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Syöpä, yksi nykyihmisen suurimmista tappajista, ilmenee virheellisen perintöainek-
sen aiheuttamana hallitsemattomasti kasvavana ja henkeä uhkaavana kasvaimena.
Muutos solun perintöaineksessa voi johtaa sen geeni-ilmentymisjärjestelmän uu-
delleenohjelmointiin. Jos tämä muutos johtaa rajattoman kasvun ja jakautumisen
mahdollistavaan geeni-ilmentymistilaan, on syntynyt syöpäsolu. Kudoksen geeni-
ilmentymistilan voi selvittää geenisirukokeella, joiden tuottamia mittauksia on suuri
määrä julkisesti saatavilla. Eri biologisten ilmiasujen lukemattomia ilmentymiä kä-
sittävän korkeaulottuvuuksisen aineiston analysointiin liittyy kuitenkin laskennal-
lisia haasteita. Erityisesti koneoppimismenetelmät ovat osoittautuneet arvokkaiksi
suuriin biologisiin aineistoihin kätkeytyvien tiedonpalasten louhinnassa.
Tässä diplomityössä esitellään koneoppimismenetelmä syöpäkasvaimen lähimmän
terveen geeni-ilmentymistilan määrittämiseksi sekä geenisäätelypoikkeaman mittaa-
miseksi. Tätä menetelmää sovellettiin hematologisiin syöpiin eli veri- ja imuku-
doskasvaimiin. Aluksi muodostettiin geeni-ilmentymisaineisto yhdistämällä 9,544
kasvain- ja normaalikudosnäytettä julkisesta tietovarastosta. Laadunvarmistuksel-
la, normalisoinnilla ja systemaattisten virheiden korjaamisella pyrittiin mahdollis-
tamaan satojen, ympäri maailmaa sijaitsevien laboratorioiden tuottaman aineiston
yhteisanalyysi.
Pääkomponenttianalyysi, klusterointi ja ohjattu luokittelu vahvistivat, että ai-
neisto todella mahdollistaa eri laboratorioiden tuottamien mittausten geeni-ilmenty-
mistutkimukset. Hematologisten syöpien esittäminen normaalikudosten geenisääte-
lyllisinä poikkeamina paljastaa niiden kehityslinjan ja asettaa ne säätelyn näkökul-
masta kantasolujen ja kypsien verisolujen väliselle alueelle. Tulokset avaavat uusia
biologisia hypoteeseja, uuden lähestymiskulman syövän parantamiseen sekä rohkai-
sevat samankaltaiseen analyysiin myös eri syöpätyypeillä.
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Cancer, one of the most common killers of modern human, is caused by malfunctio-
ning hereditary material manifesting as uncontrolled, life-threatening growth of a tu-
mor. A change in the hereditary material within a cell may cause a re-programming
of its gene-regulatory system. If the altered system leads to a gene expression sate
enabling limitless growth and replication, the cell has become cancerous. The state
of a given tissue can be determined by gene expression array experiments. A massive
amount of such measurements have been performed and placed under public access
by the research community. Analyzing this type of high-dimensional data, spanning
countless instances of separate phenotypes, however, poses computational and algo-
rithmic challenges. Machine learning algorithms, in particular, have proven valuable
in mining for pieces of knowledge hidden in biological big data.
This thesis presents a machine learning approach to estimate the nearest healthy
gene expression state of a tumor and to quantify the regulatory divergence of the tu-
mor from the normal state. The method was applied to hematological malignancies,
or cancers of blood and lymph nodes. First, a hematological gene expression data
set was integrated from 9,544 tumors and normal tissue samples available in a public
data repository. Secondly, quality control, normalization and bias correction steps
were performed to enable collective analysis of this data produced by hundreds of
laboratories worldwide.
Principal component analysis at different scales, cluster analysis and supervised
classification verified that the data set indeed allows for expression studies invol-
ving measurements from multiple laboratories. The characterization of hematolo-
gical malignancies as gene-regulatory deviations from normal tissues uncovers the
developmental lineage of the cancers and places them regulatory-wise between stem
cells and mature blood cells. The results open up new biological hypotheses, a new
approach to curing cancer and suggest that similar analyses in the context of other
malignancies could be equally fruitful.
III
PREFACE
This thesis project began at the Computational Systems Biology group at Tampere
University of Technology and was finished at the Computational Biology group at
the University of Tampere. The supervisor, all way long, has been Professor Matti
Nykter, head of the latter research group.
Working with this project has introduced me to a stimulating, interdisciplinary
field of research and a number of equally stimulating, brilliant minds. In particular,
I express my gratitude to Professors Matti Nykter and Olli Yli-Harja for guidance
and the possibility to work in such an inspiring environment. I am likewise grateful
to Docent Olli Lohi, Docent Merja Heinäniemi and Kirsi Granberg, Ph.D., for pro-
viding ideas and their indispensable insight throughout the process. Lastly, I wish to
thank my friends and family for their never-ending support during what appeared
as a never-ending project.
Tampere, May 2015
Thomas Liuksiala
IV
SISÄLTÖ
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2. Theoretical background . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.1 Cell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.2 DNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.3 Gene expression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
2.4 Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.5 Hematological malignancies . . . . . . . . . . . . . . . . . . . . . . . 7
2.5.1 Hematopoiesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
2.5.2 Molecular pathology . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.5.3 Classification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9
2.6 Gene regulatory systems . . . . . . . . . . . . . . . . . . . . . . . . . 12
2.7 DNA microarrays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.7.1 Technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
2.7.2 Data pre-processing . . . . . . . . . . . . . . . . . . . . . . . . . 16
2.7.3 Microarray databases . . . . . . . . . . . . . . . . . . . . . . . . 18
2.8 Machine learning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.8.1 Dimensionality reduction . . . . . . . . . . . . . . . . . . . . . . 20
2.8.2 Distance measures . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.8.3 Cluster analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.8.4 Classification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
2.8.5 Classifier validation . . . . . . . . . . . . . . . . . . . . . . . . . 35
3. Material and methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.1 Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
3.2 Pre-processing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
3.3 Dimensionality reduction . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.4 Cluster analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.5 Subtype prediction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.6 Lineage identification . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
4. Results and discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
4.1 Gene expression landscapes of cancer . . . . . . . . . . . . . . . . . . 46
4.2 Cluster analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
4.3 Subtype prediction . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
4.4 Cancer lineage identification . . . . . . . . . . . . . . . . . . . . . . . 54
5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
A. Appendices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
VABBREVIATIONS
ALL Acute lymphocytic leukemia
AML Acute myelocytic leukemia
AUC Area under curve
cDNA Complementary DNA
CLL Chronic lymphocytic leukemia
CML Chronic myelocytic leukemia
CV Cross-validation
DBSCAN Density-based spatial clustering of applications with noise
DNA Deoxyribonucleic acid
EM Expectation-maximization
FAB French-American-British classification of leukemia
GEO Gene Expression Omnibus
GMM Gaussian mixture model
GRN Gene regulatory network
HSC Hematopoietic stem cell
kb Kilobase, unit of length for nucleic acids equal to 1000 nucleotide
bases
KNN k-nearest neighbors
MAS 5.0 Microarray Suite 5.0
ML Maximum-likelihood
MM Mismatch
mRNA Messenger RNA
NN Nearest neighbor
PC Principal component
VI
PCA Principal component analysis
PDF Probability density function
PM Perfect match
RBN Random Boolean network
RNA Ribonucleic acid
RCT Reciprocal chromosomal translocation
RF Random forest
RMA Robust Multi-Array Averaging
ROC Receiver operator characteristic
SVM Support vector machine
TF Transcription Factor
WHO World Health Organization
11. INTRODUCTION
Cancer is a spectacularly broad family of deadly diseases. Common to all cancers is
their biological cause: an error, or mutation, in the hereditary material of a cancer
cell. This hereditary material, or DNA, contains a great number of genes. The ge-
nes hold the information a cell needs to produce proteins, which, via a variety of
functions, form the basis of practically all cellular activity, and thus, life itself. As
proteins may affect each other’s production, or expression, they form a regulatory
network whose complexity transcends human comprehension by far. When the DNA
of a cell becomes mutated, there is a small chance of this gene-regulatory network
going awry. A change in the expression of a single gene may cascade through the
network, changing the entire expression profile of the cell. If this abnormal cell hap-
pens to have enhanced replicative potential, the cell might give rise to a tumor, or
mass of cancerous cells. This horde of recklessly replicating monster cells threatens
its well-behaving neighbor cells, and, ultimately, the life of the individual itself. [1; 2]
If a gene-regulatory network is viewed as a dynamical system, then the different
cell types can be seen as attractors of that system, or expression states to which
the cell tends to even if slightly disturbed. A cancer-causing mutation, in turn,
re-models the system so that its attractor changes to a state enabling limitless
replication. [3] Studying and modeling these expression states requires measuring
the expression profiles of normal tissues and tumors. DNA microarrays have been
widely used for nearly twenty years in measuring the expression levels of all known
genes in a tissue sample. As most peer-reviewed journals require the authors of
scientific articles to submit their measurement data to public, curated repositories,
a great amount of gene expression data has accumulated over the years, accessible
to anybody interested in down-loading it. [4]
The work presented in this thesis involves integrating a set of 9,544 gene expres-
sion measurements from blood and lymph node cancers and normal blood cells. The
data set consists of measurements from hundreds of separate studies with a range
of possible study-dependent sources of bias. Thus, a major challenge of the work
is to integrate the data to enable multiple-study analyses and to validate that the
variation in the data resource in explained primarily by the biological phenotypes it
is supposed to represent and not by technical artifacts.
Normalization and the subsequent down-stream analysis of the expression data
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set requires applying computational methods developed within the fields of bioinfor-
matics and machine learning. Bioinformatics is a rapidly evolving interdisciplinary
domain of research providing the field of biology with methods of applied mathema-
tics and computer science. The rise of massively parallel — or high-throughput —
measurement technologies has turned modern biology into a heavily data-intensive
discipline, fueling the development of elaborate bioinformatic tools and resources.
Machine learning, on the other hand, is a field studying algorithmic learning from
data, or knowledge-mining. As learning is a quintessential feature of human intel-
ligence, so is machine learning an important sub-discipline of artificial intelligence.
Machine learning has proved a source of valuable approaches in making sense of
the ever growing heaps of data biologists face today. Therefore, one of the roles of
bioinformatics is finding the best machine learning algorithms to answer biological
questions, and if necessary, developing novel algorithms for the task. [5]
In this thesis, we first walk through the very basics of molecular and cancer
biology, gene regulatory systems, gene expression microarrays and machine learning.
After introducing the theory behind the work, we present the data and methods used
to analyze it. Finally, we divide the results section into four parts, the first three of
which involve standard machine learning approaches to organize and interpret the
data at various biological scales, or subsets of phenotypes. In the last part we present
a novel pan-hematological view of the regulatory divergences between cancers and
normal cells intended for generating new hypotheses of both normal and malignant
hematopoiesis.
This thesis is a in part inspired by that of Heinäniemi et al. in which TF pairs
with reversal patterns between hematopoietic lineages were uncovered from partly
the same gene expression data used in this work [6]. Here, however, the scope is broa-
dened to cover also malignancies of hematopoietic origin. A preliminary expression
analysis with the data set used in this thesis has been carried out to identify known
and novel expression patterns of small nucleolar RNAs across acute leukemias. [7]
32. THEORETICAL BACKGROUND
2.1 Cell
A cell is a fundamental building block of any living organism. The smallest of species
constitute a single cell, while larger ones, such as humans, can be composed of a
number of cells far beyond our comprehension, perhaps as much as a million billion
distinct cells. Common to all cells, regardless of species, are certain components.
These include the membrane which encloses the cell and holds it together, the cy-
toplasm which fills the space inside the membrane, as well as the hereditary material
of the organism.
One of the most profound distinctions between organisms is based on the type
of cells of which they are composed. Prokaryotes, comprising all bacteria and arc-
haea, are mainly unicellular and lack organelles, membrane-enclosed subcomponents
of the cell which are present in the other group, eukaryotes. The most notable dis-
tinguishing feature in eukaryotes — which include all animals and plants — is the
nucleus, an organelle housing the genetic material. [8] In the context of this thesis,
we will use the term "cell"to refer specifically to the eukaryotic cell, if not otherwise
mentioned.
In a multicellular organism all cells originate from a single stem cell which has
split into two daughter cells in a process called cell division. These daughter cells
have further divided as have their daughter cells and so on — eventually forming a
vast pedigree of cells. In this family tree of cells within an individual organism there
are multiple lineages in which the cells have differentiated into distinct types. In a
human there are hundreds of cell types, each carrying out its own tasks required
to keep the individual thriving. Neurons, for instance, propagate electric signals
around our body, whereas red blood cells, or erythrocytes, hold the responsibility of
delivering oxygen from our lungs to muscles. [8; 9]
The relative amount of different types of cells in the human body is regulated
by a complex system involving various signaling molecules to promote or reduce
the replication and differentiation of the required cells. For example, low blood
oxygenation increases the amount of a hormone called erythropoietin which, in turn,
stimulates the production of erythrocytes. In addition to this regulation between
cells, each cell has an internal, intricate regulatory network of protein production.
The production of proteins forms the basis of nearly all cell functionality. [9] To
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understand what it is about, let us first take a closer look at the aforementioned
genetic material.
2.2 DNA
As mentioned, cells have a fascinating capability to differentiate and specialize in
diverse, and often rather complicated, functions. The surprising complexity of these
superficially humble entities rises from the vast amount of genetic information found
in the cell together with the elaborate network regulating the utilization of that very
information. The hereditary material is deoxyribonucleic acid, commonly known as
DNA. A DNA molecule is composed of two coiled chains (or strands) of nucleotides,
and each nucleotide, in turn, contains one of the following nucleobases: guanine
(denoted by G), adenine (A), thymine (T) or cytosine (C). The two DNA strands
have complementary sequences: at every position one strand has a adenine, the other
one has a thymine and wherever there is a cytosine, the other strand has a guanine
at the corresponding position. The hereditary information is encoded in the order of
the four bases in the DNA. The entire genetic code of an organism, or the genome,
can thus be represented as a sequence of these four letters. The genome consists of
approximately 3.2 billion bases, or 3.2 million kilobases (kb). [8]
In eukaryotes, the DNA is organized as several densely packaged long molecu-
les called chromosomes. The packaged chromosomes contain proteins and protein
complexes around which the DNA is wrapped. Collectively the DNA and its attac-
hed molecules are known as chromatin. Humans normally have two pairs of twenty-
three different chromosomes, i.e. forty-six chromosomes altogether. One pair of the
chromosomes is sex-specific; females have a pair of X chromosomes, while males ha-
ve one X and one Y chromosome. Each chromosome contains up to 2000 basic units
of heredity called genes. There are an estimated number of 20,000 to 25,000 genes
altogether in our genome, each constituting a stretch of DNA anywhere in the range
of 0.2 kb to 2,500 kb. Each gene functions as a "recipe"for a functional gene product,
as we will learn in the next chapter. [9]
2.3 Gene expression
The information encoded in our DNA has biological relevance only if it is interpreted.
In other words, the genes must be expressed. In most cases, the result of gene
expression is a protein specific to the gene in question. The genetic information
of DNA is conveyed by ribonucleic acid, or RNA, to the protein level, in which it
determines the shape, and ultimately, the function of the protein. The protein of
each gene has its own function as a reaction catalyst, signaling unit or building block
of cellular structures, to name just a few instances. The flow of information from
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DNA mRNA ProteinTranscription Translation
Kuva 2.1: The central dogma of molecular biology. Genetic information of the DNA is
conveyed via mRNA to the protein.
DNA to protein via mRNA, known as the central dogma of molecular biology, is
illustrated in figure 2.1. [8]
The first stage of gene expression is known as transcription, in which the sequence
of the gene is read and a copy of it is produced in the form of RNA. The molecule
responsible for the synthesis of RNA is known as RNA polymerase. Transcription
begins as RNA polymerase attaches to the promoter region of the gene, located
next to its actual coding part. For RNA polymerase to attach to the DNA, the
promoter area must have an open chromatin structure and specific kind of proteins
known as transcription factors (TF) bound to it. Once the RNA polymerase has
bound to the promoter, it begins to slide down the DNA forming an RNA molecule
complementary to one of the DNA strands. Thus the RNA is identical in sequence
with the other strand, with one exception: in RNA, thymine is substituted by uracil
(U). [8]
In the case of some genes, the RNA resulting from transcription is a functional
unit with tasks varying from transferring other molecules to forming RNA-protein
complexes with a range of complicated functions. Often, however, the RNA molecule
is merely an intermediary product, called messenger RNA (mRNA), in the process
of protein synthesis. In such cases the RNA is translated into a protein on a cellular
machine known as a ribosome. By the ribosome, a protein is formed by connecting
amino acids into a long polypeptide chain, the sequence of which is fully determined
by the RNA sequence. There are 20 different kinds of amino acids, and each amino
acid in the peptide chain corresponds to a codon, or set of three nucleotides in the
RNA (and DNA, for that matter). Thus, the original coding sequence of the gene in
the genome has three times the amount of nucleotides than there are amino acids
in the final gene product, the protein. [8; 9]
Gene expression is how the genetic makeup, the genotype, manifests as obser-
vable traits, the phenotype. However, the presence of an identical genotype does not
necessarily lead to the same phenotype in each cell. This is due to gene regulation.
Some genes are only expressed in a specific cell type or phase in the life of a cell. The
massive orchestration of turning cells "on"and "off"allows for cells to differentiate
to highly specified tasks. For example, only certain cells in the pancreas produce
a protein called insulin, whereas beta-actin, a protein crucial in providing the cell
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with structure, is expressed in nearly every type of cells. [8]
The machinery of gene regulation involves a diversity of transcription factors and
proteins affecting the state of the chromatin. The abundance of such gene products
affects the expression of other genes, some of which may have regulatory roles as
well. Therefore, a change in the expression of a single gene may cascade through the
network of genes, changing the whole expression profile of the cell. This notion of
an expression profile, the abundance of each type of protein (or the corresponding
mRNA) expressed in a cell is one of the most important ones in this thesis. We
will approach it from a more technical viewpoint later on. But now, acquainted to
the very basics of cell biology, we are prepared for the story of the most intriguing
disease plaguing humankind ever since Adam made the definitive approach towards
Eve.
2.4 Cancer
Fine-tuned by billions of years of evolution, the inter- and intra-cellular regulatory
networks have become fairly robust to a range of disturbances. Yet sometimes —
very rarely in fact, considering the amount of cells in a human being — a single cell
may slip out of the control of its peers and begin to replicate recklessly, producing
a tumor, a mass of monster cells of its kind. This bulk of malignant, or cancerous,
cells threatens the life of its well-behaving neighbors, and, as a result, the life of
the individual itself. And indeed cancer does pose a threat to all of us: during the
lifespan of a modern human, there is a probability of over one-third to be diagnosed
with some type of cancer and a majority of the patients eventually succumb to the
disease.
Why does cancer still pester us, despite of being perhaps the most studied sub-
ject in recent biomedical research? To answer this question one must first learn to
appreciate the complexity of the disease. The complexity stems from 1) the im-
measurable distinct molecular causes of cancer 2) the intricacy of the regulatory
networks it disturbs, and 3) the evolutive nature in which tumors develop to resist
treatment and metastasize, or spread to distinct locations in the body. [2]
In the context of cell biology, the cause of cancer is most often a mutation.
Mutations are events in which the nucleotide sequence of the DNA, i.e., the genetic
code, in a cell is altered. This happens when a nucleotide is substituted with a
different one, or a segment of DNA is deleted from or inserted to a chromosome.
Mutations occur both due to replication errors when the chromosomes are copied
before a cell division as well as by the influence of certain chemicals or ionizing
radiation.
Normally, a mutation does little or no harm. Cells have a DNA repair machinery
which is often able to fix minor mutations. If the DNA damage is beyond repair,
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the cell may commit to apoptosis, a programmed cell death, or "suicide", in order
not to cause damage to its neighboring cells by possible misbehavior. But even if
the cell fails to repair its altered DNA or perform apoptosis, it is very unlikely a
randomly located small mutation is of any significant consequence, as the majority
of DNA does not code for any protein or have any other apparent crucial function.
If a mutation, however, occurs in a region coding for a protein or with regulatory
significance, such as a transcription factor binding site, it has a potential of affecting
the structure (and function!) of the protein or the rate in which it is produced. [2]
A decisive step toward cancer is taken if a mutation causes changes which lead
to enhanced cell growth or resistance to apoptosis. An increase in the growth rate
causes the DNA to be replicated at a higher rate, increasing the risk of further
mutations. Also, in a population of frequently replicating cells, the ones with a
highest growth rate are selected in an evolutive manner. Evading apoptosis, likewise,
predisposes the cell to further DNA damage. It is easy to see that these traits
form a loop of positive feedback: cancer-like properties cause even stronger cancer-
like properties. This vicious circle may last for years as mutations with malignant
potential accumulate in a cell in an accelerating rate. Eventually, when the tumor
attains the capability to metastasize, forming new, separate daughter tumors, it is
considered fully malignant and critically life-threatening. [2; 10; 11]
Cancer may arise in nearly any tissue, but some cells are more prone to uncont-
rolled growth than others. Certain tissues, including epithelia and blood, experience
a high level of normal wear and tear, and must therefore renew their cells at a steady
pace. Tissue renewal requires stem cells, which maintain the capacity to replicate
and differentiate to a number of mature cell types needed in the tissue. This very
replicative potential, while crucial in keeping us alive, perversely holds the door ajar
for cancer. In the rest of the thesis, we shall restrict ourselves to malignancies of two
related tissues undergoing constant self-renewal: blood and lymphoid tissue.
2.5 Hematological malignancies
2.5.1 Hematopoiesis
Blood, the "highway traffic"of our body, bears a close developmental relation to
lymphoid tissue, the "defense bases"housing mainly immune cells. The cells compri-
sing these two tissues descend from a common cellular ancestor residing in the bone
marrow, the hematopoietic stem cell, or shortly, the HSC. The formation of new
blood and immune cells from HSCs, known as hematopoiesis, is presented in the
diagram of figure 2.2. To maintain a constant HSC level in the bone marrow, half
of the daughter cells produced by HSC replication must remain stem cells and the
other half is engulfed in a multi-step process of cell differentiation. [8]
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Kuva 2.2: Hematopoiesis. New blood cells are formed as hematopoietic stem cells divide
and differentiate into mature cells of the blood and the immune system.
Differentiation of a blood cell can be modeled as a journey beginning from a HSC
and ending at a terminal branch in the family tree of blood cells, representing a
mature hematopoietic cell. As the differentiation progresses, the cell’s replicative
potential decreases while the hallmarks of its cellular destiny gradually strenghten.
An intermediary cell between a stem cell and a mature cell is called a progenitor or
a blast.
As figure 2.2 illustrates, the hematopoietic differentiation contains several points
in which the cell makes a "decision"between two lineages. Both stochastic events and
interleukine-mediated control of hematopoiesis determine the lineage into which a
cell ends up. The first major branch is between myeloid and lymphoid cells. Cells
of the myeloid lineage differentiate further into erythrocytes, thrombocyte-forming
megakaryocytes, monocytes and myelocytes. The lymphoid lineage produces mainly
lymphocytes, central units of the immune system. [9]
Cancers arising from hematopoietic cells are called hematological malignancies,
further divided into leukemia, myeloma and lymphoma. They all are cancers of blood
cells, but only the first two manifest primarily in blood while the latter is a cancer
of lymphoid tissue (especially lymph nodes). Leukemia and myeloma, therefore, are
liquid tumors while lymphoma is solid. All hematological malignancies, however,
may cause complications of both the circulatory and immune system. [2]
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2.5.2 Molecular pathology
A common feature of hematological malignancies is a certain type of mutation, a
reciprocal chromosomal translocation (RCT). In chromosomal translocations, two
chromosomes swap a part. A notable example of this is the so called Philadelphia
chromosome, which is caused by a translocation between chromosomes 9 and 22,
denoted by t(9;22). A translocation might connect the coding areas of two genes,
creating a fusion gene. The product of this novel gene may behave in deterious ways
or be non-functional. The fusion gene is regulated by the regulatory machinery of
only one of the fusion partners, causing domains of the other partner being expressed
at an aberrant level. This minor abnormality may have major consequences at a
cellular level via the regulatory network of genes. [2]
In blood cancers, chromosomal translocations are important driver mutations,
meaning they increase the cancer-like properties of the tumor, and are even implica-
ted as the pivotal event causing the cancer in many instances. In the aforementioned
case of the Philadelphia chromosome, the translocation fuses genes ABL1 and BCR,
resulting in a fusion gene BCR-ABL. Normally, ABL produces a protein with im-
portant signaling roles in cell differentiation and division. Fused with BCR, it is an
oncogene, cancer causing gene, by increasing replication and preventing maturation
of hematopoietic blast cells. This results in a blast crisis, in which the blood is floo-
ded with an increasing amount of immature blasts, impairing the circulatory and
immune systems, and ultimately, if untreated, to death.
Nearly all chronic myelocytic leukemias and some acute lymphocytic leukemias
are caused by the fusion of ABL1 and BCR. Incidentally, a precision drug called
imatinib has been found to inhibit BCR-ABL and, consequently, prevent blast crisis.
Although precision medicines are lacking for most cancers, knowing the genetics
behind the disease often has at least some therapeutical relevance. For this reason
(and because the cost for genetic tests has radically decreased), the presence of a
specific translocation is useful in defining subtypes of blood cancers, as we shall see
in the next section. [2]
2.5.3 Classification
There is a vast range of malignancies arising from hematopoietic cells, with dif-
ferences from both biological and clinical viewpoints. A detailed, systematic clas-
sification scheme is therefore necessary to ease diagnosis and treatment of these
neoplasms, as well as their research. The main, coarse-level classification, as men-
tioned previously, divides hematological malignancies into the following three cate-
gories [12]:
1. leukemia, arising from precursor blood cells and manifesting in bone marrow
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and blood
2. lymphoma, arising from lymphoid cells and manifesting primarily in lymphoid
tissue and
3. myeloma, arising from mature plasma B cells and manifesting in bone marrow
and blood. (As a lymphoid malignancy, myeloma is often classified as a type
of lymphoma.)
To further divide these main classes into meaningful subtypes, several measurable
attributes have been used, including [12; 13]
1. clinical features, such as where and how the disease manifests
2. morphology, i.e. what the cancer cells look like under microscope
3. immunophenotype, defined by the protein content of the cancer cell surface
membrane (i.e. surface markers) and
4. cytogenetics, especially chromosomal aberrations present in the cancer cells.
Of these attributes, the clinical features have been traditionally the easiest to
detect and, naturally, most relevant to therapy. Morphology is also relatively easy
to observe and, thus, has been used extensively to classify blood cancers. However,
its relevancy in any respect is questionable [14]. Immunophenotyping, while more
costly and laborious than microscopic examination, is shown to reveal — to some
extent — the lineage and maturation level of the cell from which the cancer is
originated. Indeed, the presence of surface markers has been used in both diagnosis
and study of blood cancers. [15]
Cytogenetical measurements of chromosomal aberrations, such as translocations
or abnormal numbers of chromosomes, are useful in studying the cause of a disease.
However, until the advent of precision drugs about fifteen years ago, they have been
of limited clinical use. Now, as genetic measurements are commonplace in cancer
research and precision medicines are being sought after, the relevance of genetic
features as disease subtype classifiers has been acknowledged. Furthermore, not only
chromosomal abnormalities have been shown to explain the disease and be useful
in planning personalized treatment, but also more subtle differences in the genome,
transcriptome, proteome and epigenome as well. These so called molecular markers
of disease have been a central topic in cancer research for the recent years. [16; 17; 18]
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Leukemia
Within leukemia, there are two major distinctions between subtypes of the disease.
The first one, based on the main hematopoietic lineage giving rise to the cancer,
divides leukemias into myeloid and lymphocytic types. The second distinction, a
clinical one, divides them into acute and chronic diseases. Combined, these two
distinctions yield four main categories of leukemia: Acute myeloid leukemia (AML),
Chronic myeloid leukemia (CML), Acute lymphocytic leukemia (ALL) and Chronic
lymphocytic leukemia (CLL).
The acute forms of myeloid and lymphocytic leukemia are typically caused by a
low number of mutations (often one single translocation) in hematopoietic progenitor
cells and they progress fast. Chronic leukemias, on the contrary, often take years to
develop, cumulating a higher number of diverse mutations in typically slightly more
mature blast cells than their acute counterparts. This is reflected in the fact that
acute leukemias are far more common in children than chronic leukemias. Also, in
the case of acute leukemias, translocation-based classification is more relevant as the
chromosomal aberrations explain the disease to a longer extent. [2; 17]
Acute leukemias were previously classified using a morphology-based French-
American-British (FAB) classification dating originally from 1976 [19]. As the cli-
nical importance of chromosomal aberrations became apparent, the World Health
Organization (WHO) released its own translocation-based classification in 2001,
which was updated in 2008 [13; 20]. The WHO classification of AML is shown in
table 2.1 and that of ALL in table 2.2. In the tables, the translocations are listed
with their corresponding fusion protein. In the WHO classification of AML, the pre-
viously used FAB classes are included as provisional subtypes within AML cases
which are not otherwise specified.
Taulukko 2.1: 2008 WHO classification of acute myeloid leukemia (AML). [20]
AML with recurrent genetic abnormalities
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
AML with t(15;17)(q22;q12); PML-RARA
AML with t(9;11)(p22;q23); MLLT3-MLL
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1
Provisional entity: AML with mutated NPM1
Provisional entity: AML with mutated CEBPA
AML with myelodysplasia-related changes
Therapy-related myeloid neoplasms
AML, not otherwise specified
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Taulukko 2.2: 2008 WHO classification of acute lymphocytic leukemia (ALL). [20]
Precursor B-ALL
Precursor B-ALL, NOS
Precursor B-ALL with recurrent genetic abnormalities
Precursor B-ALL with t(9;22)(q34;q11.2);BCR-ABL 1
Precursor B-ALL with t(v;11q23);MLL rearranged
Precursor B-ALL t(12;21)(p13;q22) TEL-AML1 (ETV6-RUNX1)
Precursor B-ALL with hyperdiploidy
Precursor B-ALL with hypodiploidy
Precursor B-ALL with t(5;14)(q31;q32) IL3-IGH
Precursor B-ALL with t(1;19)(q23;p13.3);TCF3-PBX1
T-ALL
Lymphoma
Lymphomas, as solid tumors, differ from leukemias in many ways in respect to classi-
fication. Unlike in leukemias, the anatomical location and tissue harboring the tumor
is an important attribute used to define subtypes of lymphoma. Also, because solid
tumors typically require a longer time to accumulate cancer-promoting mutations,
the genetic makeup is more complex, decreasing the relevancy of a translocation-
based classification as in acute leukemias. Table 2.3 lists the main categories of the
2008 WHO lymphoma classification, mainly based on the sub-lineage within the
main lymphoid lineage [21]. Most categories harbor a large number of subtypes dif-
fering in various clinical, pathologic, or biologic features. In the WHO classification
scheme, multiple myeloma is listed as a subtype of mature B-cell neoplasms. [22]
Taulukko 2.3: 2008 WHO classification of the main types of lymphoma. [21]
Mature B-cell neoplasms
Mature T-cell and NK-cell neoplasms
Hodgkin lymphoma
Histiocytic and dendritic cell neoplasms
Posttransplantation lymphoproliferative disorders (PTLDs)
2.6 Gene regulatory systems
In 1957, Conrad Waddington presented his well-known epigenetic landscape of cel-
lular differentiation, pictured in figure 2.3 [23]. The landscape is a metaphor of gene
regulation-mediated differentiation of the cells of an organism, in which a ball rol-
ling down a grooved hill represents the cell as it maturates. At the top of the hill,
the ball represents is a pluripotent stem cell, but as it rolls down the landscape, it
ends up in a groove (developmental lineage) and further sub-grooves (sub-lineages),
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Kuva 2.3: Waddington’s epigenetic landscape. The ball rolling down the grooved hill repre-
sents a differentiating cell. The valleys at the root of the hill correspond to distinct cell
types. [23]
finally stopping at the root of the hill in a valley representing a specific, fully ma-
ture cell type. With the word epigenetic, Waddington refers to all gene-regulatory
activity defining the phenotype as opposed to the actual genetic information, or
DNA-sequence, which is assumed to be stay unaltered during differentiation. Later,
epigenetics has been defined more strictly as heritable modifications of a chromoso-
me not affecting the DNA sequence. For convenience, however, we will stick here to
Waddington’s broader definition of the term. [24]
Besides being an illustrative metaphor of the complex system giving rise to
multiple, distinct cell types in spite of identical hereditary material, Waddinton’s
landscape model does not defy exact formulation. One of the first models of epige-
nesis, filling the causative gap between DNA and the diverse range of distinct cell
types it enables, was proposed in 1967 by Stuart Kauffman. Introducing random
Boolean networks (RBN) as discrete, dynamical models of gene regulatory networks
(GRN), Kauffman suggested that different cell types are attractors, or stable states,
of the network. The concept of an attractor is central in the theory of dynamical
systems. In a dynamical gene network it corresponds to a gene expression state to
which the system tends to even if slightly disturbed. A sufficiently large perturba-
tion, however, may cause the system to drift to another attractor. In Waddington’s
landscape, the attractors are the valleys and an attractor-switching perturbation
would be one which pushes the ball over the hill separating two valleys. [26]
Perturbations of the GRN may be due to impulses from the environment as well
as the inherent stochasticity of inter- and intracellular regulation. During the process
of differentiation, randomness plays an important role in defining cellular fate [25].
However, once the cell is terminally differentiated, robustness to disturbances is de-
sirable to maintain the current state, or gene expression profile. Therefore, GRNs
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Kuva 2.4: A gene regulatory network. Genes A and B induce other genes, or increase
their expression. C, on the other hand, is a repressor: it decreases the expression of genes,
including itself. By self-repression, C regulates its own expression level. A regulates its own
expression level, too, but indirectly by inducing a gene (B) which induces its repressor (C).
Genes A, B and C form the regulatory core of this GRN while D and E merely express the
effects of their regulators.
wired such that their attractors are sufficiently stable enjoy a selective advantage. Es-
sential for any self-regulative system are negative feedback loops. Negative feedback
ensures that changes in the state of the system are moderated by adversary effects.
Gene regulatory-wise, this means that GRNs must contain self-repression. [28]
Figure 2.4 shows a small GRN. Three of its five genes have regulatory functions:
they induce or repress other genes (or themselves). The regulatory genes form the
core of the GRN as changes in their expression affects the expression state of the
whole system. Non-regulatory genes have no effect on the expression profile outside
their own expression. In a real-life GRN, the regulatory core composes of TFs and
other genes with regulatory effects. Two types of control circuits are presented in
figure 2.4: direct and indirect self-repression. Both contribute to the stability of the
expression profile. [1]
Any change in the wiring of a GRN may change its attractor. Biologically, a
mutation affecting any regulatory connection of the GRN is such a change. As the
system changes, so does its epigenetic landscape. Thus, cancer can be seen as a
re-wired GRN which leads to new attractors being formed, corresponding to gene
expression states enabling limitless replication. Figure 2.5 illustrates the case. The
normal maturation process is halted by a new attractor which retains the replicative
potential of the cell. In leukemia, for instance, such an attractor-state is the cause
of blast crisis. This model, thus, places tumorigenesis in the context of cellular
differentiation, only with an altered epigenetic landscape. [28]
So far, modeling a genome-wide GRN has been a daunting task. Uncovering all the
regulatory connections and quantifying their degree of inhibition or repression, not
to mention their combinatorial effects, requires a great amount of biological research.
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Kuva 2.5: Cellular maturation. In cancer, normal differentiation (A) is halted by rewiring
the gene regulatory network, forming a new, cancerous attractor in the gene expression
space (B).
Therefore, systemic properties of whole-genome regulatory models have been studied
with GRNs making very strong simplifying assumptions, such as binary expression
states and random regulatory effects in RBNs. Another approach is to restrict the
GRN to a small sub-network and attempt to model its regulatory connections in
detail using differential equations. This, of course, enables analyzing only a fraction
of the functionality of the entire system. [27]
2.7 DNA microarrays
2.7.1 Technology
For the last fifteen years, the most widely used technology to measure genome wide
features from tissue samples or cell cultures has been the DNA microarray. Most
importantly, microarrays allow measuring the expression levels of all genes in the
genome in parallel at a reasonable cost. Whole-genome expression measurement
yields a snapshot of the expression state and can be used to characterize and study
the mechanisms of intracellular processes, both normal and abnormal. [29; 30]
DNA microarrays are small chips with DNA oligonucleotides called probes at-
tached to its surface. In a microarray experiment, complementary DNA (cDNA),
obtained by reverse-transcribing RNA from a sample, is labeled by laser-excitable
cyanine dyes. Then it is hybridized to the probes on the chip. Un-hybridized cDNA
fragments which do not match any probe, are washed out. Finally, the amount of
cDNA hybridized to the probes is measured by detecting the emission intensity of
the labels when disposed to laser of the dye-specific wavelength. Some microarrays
use a two-channel method in which two separate samples (disease versus healthy
control, for example) are hybridized to the same chip with separate labels. In this
thesis, however, we focus on analysis of data measured with single-channel chips in
which one chip per sample is used. [31]
Whole-genome expression microarrays are highly parallel, or high-throughput,
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measurement platforms. For this reason, the analysis of the results requires algo-
rithms and computation, beginning from the very normalization of the raw inten-
sities detected from the chip. A multitude of elaborate down-stream analyses of
gene expression data have been developed during the years, including enrichment
analyses, time-series analyses, and several approaches harnessing the full power of
supervised and unsupervised machine learning. [30; 31]
2.7.2 Data pre-processing
In any microarray experiment, the raw intensity measurements should be subjec-
ted to quality control and normalization to address technical biases and artifacts
of various types. Additional platform-dependent pre-processing steps may also be
necessary in transforming the probe intensities to gene expression values. Several
algorithms have been developed by technology providers and academia with various
approaches to normalization and other pre-processing steps. For Affymetrix GeneC-
hips arrays, the most popular pre-processing algorithms are Microarray Suite 5.0
(MAS 5.0) and Robust Multi-array Average (RMA) [32; 33; 34].
Preliminary quality control
Before normalization, it is appropriate to carry out preliminary quality control for
the raw intensities of microarray experiments in order to rule out experiments failed
due to a technical or human errors. Data should be deemed unusable if a high
number probe intensities are saturated at the maximum value or totally undetected.
In addition, if the distribution of the raw intensities appears irregular (for example,
multimodal distribution), it is reasonable to consider the experiment failed. If the
study comprises several microarray experiments, the distributions of intensities can
be compared by a visual inspection of box plots, for example, to detect outlier
distributions. [30]
Background correction
Most pre-processing algorithms perform background correction, i.e., noise removal,
to the raw intensities before normalization. Background correction is based on the
assumption that the intensity values can be represented as a sum of the true signal
and noise. In MAS 5.0, the noise is estimated from the 2 % of probes with lowest
intensities in a local manner [32]. In RMA, the intensity s is assumed to be composed
of the true signal x and noise y. Signal s is modeled using a random variable S:
S = X + Y, (2.1)
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in which the true signal is modeled as an exponential distribution X ∼ Exp(α) and
the noise as a normal distribution Y ∼ N(µ, σ). This allows the expected value of
X, given s to be found by
E(X|S = s) = a+ σ φ(a/σ)
Φ(a/σ)
, (2.2)
where a = s−µ−ασ2, φ is the probability density function of a normal distribution
and Φ is its cumulative density function. The parameter values are estimated using
all of the intensities on the array. RMA, thus, does not assume location-dependent
noise unlike MAS 5.0. [33]
Normalization
The objective of normalization is to remove the so called chip-effect, or the batch
effect between multiple microarray experiments. Without normalization, comparison
studies involving several chips are likely to suffer from the chip-effect. All approaches
to cross-chip normalization attempt to reduce the difference in intensity distributions
between arrays. In MAS 5.0, the data is scaled so that the mean (excluding the lowest
2% of values) of each array is equal. On log-scale, the scaling corresponds to shifting
without affecting the shape of the distribution. [32] RMA uses a stronger method
called quantile normalization, which forces the distributions of each chip to be equal.
The steps in quantile normalization are:
1. Represent the d intensities of n arrays as a matrix I ∈ Rd×n
2. Obtain Is by sorting I column-wise
3. Calculate m ∈ Rd, the row-wise mean of Is: mi = 1n
n∑
j=1
Isi,j,∀i ∈ [1, d]
4. Obtain the quantile-normalized matrix Iqn by replacing each element in the
unsorted I bymi, where i is the row index of the corresponding element in the
sorted matrix Is
Assuming the ideal, unbiased data are from equal distributions, quantile norma-
lization is a more powerful approach for cross-chip studies. It is, however, vulnerable
to outliers in data, making preliminary quality control necessary. [33]
Correction for nonspecific hybridization
To address the issue of nonspecific hybridization, i.e. cDNA fragments with non-
complementary sequences hybridizing to a probe, Affymetrix GeneChips have a
mismatch (MM) probe for each normal probe, denoted perfect match (PM). The
MM probe is equal to the PM probe except for the base in the middle of the probe,
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which is replaced by its complementary base. The signal intensity at MM probes are
supposed to reflect the amount of nonspecific hybridization of the corresponding PM
probe. MAS 5.0, therefore, robustly estimates the level of nonspecific hybridization
from MM intensities and subtracts them from the PM intensities. However, using the
MM intensities has proven problematic in several ways, which is why RMA, among
other methods, ignores the MM probes altogether and, thus, does not attempt to
correct for nonspecific hybridization. [32; 33]
Summarization
In Affymetrix GeneChip arrays, multiple probes (a probe set) are used in measuring
expression of a single gene. Therefore, a separate summarization step is required to
transform the probe intensities into gene expression values. Both MAS 5.0 and RMA
use robust estimations of probe set medians. MAS 5.0 uses a method called Tukey’s
bi-weight while RMA uses median polish. In median polish, the k probes belonging
to the same probe set are used to obtain gene expression values as follows:
1. Represent the k probe intensities of n arrays as a matrix P ∈ Rk×n
2. Initialize P∗ to P
3. Update P∗ by subtracting the row-wise median from its columns
4. Update P∗ by subtracting the column-wise median from its rows
5. Repeat steps 3. and 4. until the medians converge to zero or maximum number
of iterations (five by default) is reached
6. Obtain the median-polished matrix Pmp by subtracting P∗ from P
7. Obtain the probe set expression value for the ith array by taking the mean of
the ith column of Pmp
The significant difference between the approaches of MAS 5.0 and RMA is that
Tukey’s bi-weight is performed one chip at a time, whereas median polish uses
information from all chips in estimating probe affinity effects. In this respect, too,
RMA uses a method which is more powerful but also vulnerable for low-quality
arrays. The summarization step is performed before normalization in MAS 5.0, and
after in RMA. [32; 33]
2.7.3 Microarray databases
The rise in popularity of high-throughput measurements in biology has created a
demand for means of effortless data sharing. The true power of microarray expe-
riments has been suggested to be in multi-experiment studies. Furthermore, most
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academic journals require the data used in research articles to be shared via public
repositories accompanied with sufficient metadata. Several repositories are available
for microarray data, the largest being Gene Expression Omnibus (GEO) curated
by The National Center for Biotechnology Information (NCBI) [4]. Microarray ex-
periments submitted to most public repositories must contain metadata complying
with the Minimum Information about a Microarray Experiment (MIAME) standard
created by The Functional Genomics Data (FGED) Society [35].
2.8 Machine learning
For decades, the cost of storing and processing data has fallen exponentially as
predicted by the well-known Moore’s law [36]. As a result, the amount of data
gathered and piled in databases of all types has risen at an accelerating rate. In this
age of amassing piles of data, there is more demand than ever for the ability to draw
valuable information, or knowledge, from vast data sets. Due to the development of
high-throughput biological measurement technologies, this data issue has not spared
the fields of biology and medicine. DNA microarrays were one of the first technologies
creating major data interpretation problems in biology and they were soon followed
by the widespread utilization of massively parallel next-generation DNA- and RNA
sequencing technologies [37].
Fortunately enough, before the pervasive data analysis problem hit all fields of
research and business capable of producing big data, established theories of advanced
data analysis had already been developed. Researchers, predominantly in computer
science and applied mathematics, had created a range of algorithmic approaches to
learn (i.e., acquire knowledge) from data, known commonly as the field of machine
learning. Lying partially within the framework of artificial intelligence, machine
learning relies on theories of statistics and optimization to develop computational
methods giving humans and machines understanding of real-world problems from
markedly different types of data [38].
Emphasizing its ability to discover novel knowledge from superficially uninforma-
tive data, machine learning is often viewed as knowledge mining. Yet another facet
of this field is pattern recognition, as distinguishing patterns is in the very crux
of all data interpretation, for both humans and machines. Recognizing patterns is
especially apparent in such applications of machine learning as face or voice recog-
nition, but it is also present in, for instance, recognizing complex patterns of gene
expression, even though the patterns are not necessarily visible or comprehensible
for humans. Here, in fact, lies the true power of machine learning: mimicking the
human ability to learn, it extends the skill to amounts of data and complexity of
patterns beyond the memory or processing capacity of a human brain. [38; 39]
Most methods of machine learning can be classified as either unsupervised or su-
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pervised learning. In unsupervised learning, the data is unlabeled, meaning that the
data points, or objects represented by a number of attributes, are of unknown class.
This corresponds, for instance, to a set of images without any captions. The ima-
ges may represent different objects, but no information of their content is provided.
Yet, despite the lack of labels, the data may yield a mass of valuable information.
This requires organizing and analyzing the data by methods emulating the human
ability to understand and explain unprecedented input perceived by our sensory or-
gans. The goal, simply, is to describe the data in a compact and, if possible, human-
comprehensible way. Thus, unsupervised learning is an exploratory approach to data
interpretation: the outcome, at best, is both useful and surprising. As opposed to its
unsupervised counterpart, supervised learning requires labeled data. The objective
is to learn to label the data points using their attribute values and to apply the
learned ability to classify new, unlabeled objects.
2.8.1 Dimensionality reduction
Some times, the data encountered in machine learning is of high dimensionality.
This means that the number of attributes used to represent the objects is high,
for example several thousands. High dimensionality may cause several problems,
including 1) inability to visualize the data, 2) excessive memory usage in storing it, 3)
disproportionate processing time in analyzing it, and 4) the curse of dimensionality.
The notorious curse of dimensionality is a notion based on the assumption that
the number of data points (observations) sufficient to describe the patterns in data
grows exponentially with the dimensionality. In the case of thousands of variables
— not at all abnormal in high-throughput biology — the amount of observations
needed could be astronomical. [38; 40]
Dimensionality reduction is an approach to evade the problems caused by high
dimensionality by reducing the number of dimensions in a meaningful way. It relies
on the notion of intrinsic dimensionality, according to which the data can be descri-
bed in a lower dimensionality if it contains redundant dimensions (attributes) [41].
Fortunately, redundancy is often encountered in high dimensional data. In such ca-
ses, the dimensionality can be reduced — often to a fraction of the original — with
only a marginal information loss. [38] Dimensionality reduction, thus, can be seen a
method of data compressing.
A naïve approach to dimensionality reduction would be to discard the dimen-
sions deemed uninformative by some pre-defined criteria. This is known as feature
selection, if the dimensions preserved are considered features to be used in further
analysis. Often, however, it is possible to combine the original dimensions in an ap-
propriate way to reduce the dimensionality while preserving information from up to
all of the original dimensions. Such approaches are methods of feature extraction.
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One of the most used (and simplest) methods of dimensionality reduction is the
principal component analysis (PCA). In PCA, the data is transformed by rotating
the coordinates such that the first of the new dimensions, called principal com-
ponents (PC), has the highest variance (and hence, information). The second PC
contains the second most variance and so on. It may be appropriate to choose the
number of PCs by adjusting the total amount of variance of the transformed data to,
say, 90% of the original variance. If the data is to be visualized as a scatter plot, the
first two principal components can be used (or three, in case of a 3D visualization).
The steps of PCA include 1) constructing a covariance matrix from the original
data matrix, and 2) performing the eigenvalue decomposition of the covariance mat-
rix. The eigenvectors sorted in descending order of their corresponding eigenvalues
define the PCs. Each resulting PC is a linear combination of the original dimensions.
Therefore, PCA is a linear dimensionality reduction method. If the dimensions hold
nonlinear relations, a nonlinear method may be able to reduce the dimensions more
efficiently. However, the theory of nonlinear dimensionality reduction as well as the
interpretation of the resulting dimensions is more complicated. Due to its simplicity,
PCA may be a reasonably useful method even in such cases. [40]
2.8.2 Distance measures
Any approach to group or classify data computationally requires an explicit or
implicit means of measuring the similarity — or, alternatively, dissimilarity —
between observations. As the dissimilarity of two observations is proportional to
their distance in the attribute space (or at least indicative of it), these ways of de-
termining dissimilarity are called distance measures. To define a distance measure,
let the data consist of observations xi, i ∈ [1, n]. Intuitive properties for the distance
between xi and xj, or, d(xi, xj), include symmetricity [42]
d(xi, xj) = d(xj, xi),∀i, j ∈ [1, n] (2.3)
and non-negativity [42]
d(xi, xj) ≥ 0,∀i, j ∈ [1, n]. (2.4)
These two conditions are natural defining properties of a distance measure as the
concepts of asymmetrical or negative distance do not correspond to our intuitive
understanding of distance. The measure is considered a distance metric, if it addi-
tionally satisfies the triangle inequality [42]
d(xi, xj) ≤ d(xj, xk) + d(xk, xj),∀i, j, k ∈ [1, n] (2.5)
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and reflexivity [42]
d(xi, xj) = 0 ⇐⇒ xi = xj,∀i, j, k ∈ [1, n]. (2.6)
The conditions of triangle inequality ("the shortest distance is as the crow flies")
and reflexivity ("zero distance means identical observation") are likewise rather in-
tuitive, but in some cases, a distance measure not satisfying them might be used for
faster or otherwise better performance [43].
Many machine learning algorithms require the user to select the most appropria-
te distance measure to be applied. The selection may significantly affect the perfor-
mance of the algorithm. The main thing to take into account in distance measure
selection is the type of the data. One has to know the types of the attributes (or
features extracted from them). One way to classify attributes is the type of scale of
their possible values. The four main scale types are [43; 44]:
1. Nominal scale. The attribute values are categories which cannot be ordered
quantitatively. Example: species (Homo Sapiens, Mus Musculus).
2. Ordinal scale. The attribute values are quantitative categories, but the dif-
ference between two successive categories has no precise definition. Example:
verbal expression of size (small, medium, large).
3. Interval scale. The attribute values are quantitative, and the difference (inter-
val) between two values can be expressed numerically. However, the relation
of two categories is not meaningful, i.e. the origin of the scale is arbitrary.
Example: Celsius scale (in which value zero does not imply zero heat energy).
4. Relative scale. The attribute values are quantitative, and both the difference
and relation between two values have meaningful interpretations. Example:
Kelvin scale.
Nominal attributes are always qualitative, i.e., their value does not represent the
amount of any property. The other three types are quantitative, but only attributes
with interval and relative scales are numerical. Qualitative and numerical variables
have separate distance measures, of which we will present some of the most important
ones. [43]
Distance measures for numerical variables
Numerical variables include both discrete and continuous variables, and the distance
measures presented here apply to both types. Perhaps the most common distance
measure, euclidean distance, which corresponds to physical distance based on ort-
hogonal coordinates, is formulated for l-dimensional vectors as [45]
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L2(xi, xj) =
√√√√ l∑
k=1
(xj,k − xi,k)2. (2.7)
Euclidean distance can be generalized to Minkowski distance, the Lp-norm [45]:
Lp(xi, xj) =
p
√√√√ l∑
k=1
(xj,k − xi,k)p. (2.8)
Setting parameter p to 2 yields euclidean distance, which, therefore, is also known
as L2-norm. A simpler distance measure, L1-norm or Manhattan distance is defined
as
L1(xi, xj) =
l∑
k=1
|xj,k − xi,k|. (2.9)
Letting p approach infinity gives the L∞-norm
L∞(xi, xj) =
l
max
k=1
|xj,k − xi,k|. (2.10)
All of the distance measures defined by Lp-norm fulfill the criteria for a metric [39].
Out of the Lp-family, other common measures for dissimilarity include correlation-
based distances. They are defined as
dcorr(xi, xj) = 1− r(xi, xj), (2.11)
in which r(xi, xj) is the correlation coefficient of the two observations. The most
common correlation coefficient is the Pearson’s r:
rpearson(xi, xj) =
l∑
k=1
(xi,k − x¯i)(xj,k − x¯j)√
l∑
k=1
(xi,k − x¯i)2
l∑
k=1
(xj,k − x¯j)2
, (2.12)
where x¯i and x¯j denote the means of xi and xi, respectively. A more robust coefficient
is Spearman’s r:
rspearman(xi, xj) = rpearson(xˆi, xˆj), (2.13)
in which xˆi and xˆj are xi and xj with they elements replaced by their ranks, i.e.,
integers between 1 and l. Spearman’s correlation is able to reveal many non-linear
correlations better than Pearson’s correlation and it is more robust against out-
liers. The cost of robustness, however, is a decrease in statistical significance of the
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coefficients as the data resolution is smaller. [40]
Distance measures for categorical variables
A simple and popular distance measure for observations of categorical variables is
Hamming distance. It is the count of attributes which have non-identical values in
the two observations [42]:
dhamming(xi, xj) =
l∑
k=1
Sk, (2.14)
where
Sk =
1 if xi,k 6= xj,k0 if xi,k = xj,k.
Hamming distance applies for any categorical attributes, including binary va-
riables. For binary variables in which 1 signifies the presence of a property and 0 its
absence, Jaccard index is a widely used similarity measure. It is defined as the ratio
of shared properties to all properties present in either observation [45]:
sjaccard(xi, xj) =
l∑
k=1
(xi,k ∧ xj,k)
l∑
k=1
(xi,k ∨ xj,k)
. (2.15)
where the elements of the observations are interpreted as Boolean variables. Jaccard
distance is defined as the complement of Jaccard index:
djaccard(xi, xj) = 1− sjaccard(xi, xj) =
l∑
k=1
(xi,k ∨ xj,k)−
l∑
k=1
(xi,k ∧ xj,k)
l∑
k=1
(xi,k ∨ xj,k)
. (2.16)
Jaccard distance assumes properties present in either observation contribute to
their dissimilarity, but properties absent in both observations have no effect. This
is intuitive for rare properties (the absence of a rare genetic variant in a patient is
a rather uninformative fact), but for common properties it works less well. [42]
2.8.3 Cluster analysis
In acquiring new knowledge, one important ability is grouping objects. Encountered
by a set of objects unseen before, it is natural, easy and often useful for a human to
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Kuva 2.6: Cluster analysis. The left panel shows two-dimensional data with three apparent
groups. The right panel visualizes the result of a cluster analysis which was able to detect
the groups.
divide the objects into groups based on their parent attributes: size, color, material
and so on. In unsupervised machine learning, grouping unknown objects, called clus-
tering or cluster analysis, is one of the most important ones. To detect meaningful
groups among a set of observations is a central means of gaining information of the
structure, or patterns, of the data. Clustering can also be seen as a data reduction
method, in which the observations are replaced by artificial observations called pro-
totypes representing the clusters. Furthermore, clustering attributes of a data set
can be used to reduce the dimensionality. [43]
Figure 2.6 attempts to explain the idea of cluster analysis. The left panel of
the figure shows a set of observations represented as two-dimensional data points.
The two axes could correspond to numerical attributes such as height and weight.
Inspecting at the data set visually, it is apparent that the points tend to three
clusters. Thus, the data contains three natural clusters. The right panel of figure 2.6
shows the output of the mental clustering human brains automatically perform.
Each observation has been assigned to one of the three groups, and it appears
likely that these three groups represent three truly different types of objects. The
objective of cluster analysis is to similarly detect the "true"clusters present in the
data, especially when the dimensionality and complex cluster structure require the
memory and processing capacity of a machine.
Clustering, performed by a machine, requires the process to be formulated as an
algorithm. Various types of algorithms have been proposed and used in clustering,
each of which have their own strengths and weaknesses. All methods, explicitly or
implicitly, are designed to perform a two-objective optimization by simultaneously
1) minimizing the variance of data within clusters, or cohesion, and 2) maximizing
2. Theoretical background 26
the difference between clusters, or separation. Furthermore, measuring the cohesion
and separation requires a distance measure to evaluate how dissimilar two observa-
tions are. Most clustering methods can be classified as centroid-based, model-based,
hierarchical or density-based approaches. [43; 46]
Centroid-based clustering
In centroid-based clustering, each cluster is defined by a centroid which is the —
appropriately defined — most representative (true or artificial) observation of that
cluster. The most simple centroid-based clustering algorithm, k-means clustering,
is perhaps the most popular of all clustering methods. In k-means clustering, the
observations are partitioned into k clusters, each of which are defined by its centroid.
The algorithm consists of the following steps [40]:
1. Initialize k cluster centroids in the attribute space.
2. Assign each observation to the cluster whose centroid is closest.
3. Update centroids to new cluster means.
4. Return to step 2 if any centroid moved more than predefined ε.
As the centroids converge, the partition reaches a local optimum. The popularity of
k-means clustering stems from its speed and simplicity. However, a notable drawback
of the method is that k, the number of clusters, must be defined before clustering.
This requires more insight of the structure of the data than is usually available. One
way to avoid the problem is to perform the clustering with multiple values of k and
choose the partition which performs best by an objective clustering performance
measure. [42; 40]
Density-based clustering
Density based algorithms approach the clustering problem by defining clusters as
data point dense-areas in the attribute space, separated by sparse areas. The most
well-known density based clustering algorithm is DBSCAN (density-based spatial
clustering of applications with noise). DBSCAN uses two user-specifiable parameters
to assign each data point to one of the following three types [47]:
1. A cluster core point, if it has at least p other points within a distance of ε.
2. An outlier, if it has no neighbors within ε.
3. A cluster edge point, if it has at 1 to p− 1 core points within ε.
2. Theoretical background 27
Any group of connected core points and the edge points directly connected to
them is considered a cluster. The outliers are considered members of no cluster. The
number of clusters, thus, emerges from DBSCAN and is not required as a parameter.
Other advantages of the method include its ability to detect clusters of irregular and
concave shapes and its explicit notion of outliers, making it a rather robust method.
The main disadvantage, perhaps, is the need to specify the parameters p and ε. Also,
detecting clusters which overlap or have variable densities has proven problematic
with standard DBSCAN, leading to more adaptive — and complex — versions of
the algorithm to be developed. [48; 49]
Model-based clustering
As opposed to the somewhat heuristic k-means clustering and DBSCAN, model-
based clustering offers a more statistically sound approach to grouping data. It
assumes the data can be represented as a mixture model of consisting one probability
density function per cluster. A priori knowledge is required in defining the number of
clusters, k, and the type of distributions (e.g., Gaussian). The clustering algorithm
will then seek for locally optimal parameters for the distribution of each cluster
and assign each observation to the most likely cluster based on the distributions.
Here, however, we encounter a chicken-or-egg-problem: to fit the distributions to
the data the cluster members must be known, but, to define the cluster members,
the distribution parameters must be known. This type of problem is solved using
an iterative algorithm known as expectation maximization (EM). In constructing a
mixture model using EM, the distribution parameters are first initialized and then
the following two steps are iterated [39]:
1. Expectation, or E-step. Using the distribution parameters, calculate the cluster
membership likelihoods for each observation.
2. Maximization, or M-Step. Update the distribution parameters are to fit the
membership likelihoods. Unless the changes were insignificant, return to E-
step.
With Gaussian mixture models (GMM), the algorithm converges to a local optimum
relatively fast. The main benefits in model-based clustering are that prior knowledge
of the clusters can be incorporated by selecting the model accordingly and that the
predefined model defies overfitting to data, if the model complexity is restricted.
However, if the selected model (i.e. distribution type) is inappropriate, model-based
cluster analysis may produce useless results. If an educated model selection is not
possible, a different clustering method, hierarchical clustering for instance, can be
more suitable. As a side-note, it is interesting to notice that the k-means algorithm
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Kuva 2.7: Cluster analysis of data with a hierarchical structure. The left panel shows two-
dimensional data. The middle and right panels visualize the results of cluster analyses with
three and six clusters, respectively. Both analyses yield apparently meaningful results, but
at a different level of detail, or scale.
performs essentially EM for spherical Gaussian clusters. As such, k-means can also
be seen as an instance of model-based clustering. [39; 38]
Hierarchical clustering
Cluster analysis normally — especially when predefined k is used — yields informa-
tion of the data only at a certain scale. Data can have both coarse and fine structure,
but often it is up to the human interpreting the results which scale is most infor-
mative. Figure 2.7 shows a two-dimensional data set which has clustered structure
at two different scales. The three main clusters can be further divided into smaller
clusters. An approach to uncover the hierarchical structure of a data set is called
hierarchical clustering.
In hierarchical clustering, the data is assumed to be composed of clusters with sub-
clusters, which, in turn, may have sub-clusters and so on. Any algorithm performing
hierarchical clustering will attempt to discover this hierarchy and produce a dendro-
gram, a tree-like graph visualizing the cluster structure. A flat (non-hierarchical)
partition of the data can be obtained by using the dendrogram to define the ap-
propriate level of detail and, hence, k. In other words, one benefit of using hierarc-
hical clustering is that k can be defined in a rational way. [42; 39]
Figure 2.8 presents a two-dimensional data set and a dendrogram presenting its
structure. The height at which the branches of the graph are joined is proportio-
nal to the distance between the clusters represented by the respective branches. In
figure 2.8, we see that there are three natural clusters present: one consisting of ob-
servations a, b and c, another one consisting of d, e and f, and the last consisting of
g, h, i and j. This can be seen from the dendrogram in which there is a significant
gap between the second and third branch.
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Kuva 2.8: A two-dimensional data set and a dendrogram presenting its structure. The
dendrogram reveals three main clusters with varying numbers of subclusters.
Algorithms of hierarchical clustering can be divided into agglomerative and divi-
sive methods. In agglomerative clustering, the cluster hierarchy is constructed from
the bottom to the top, while divisive algorithms move from top to down. The ag-
glomerative approach, thus, begins with unclustered data and combines two clusters
(possibly consisting of a single data point) at a time. In divisive clustering, the data
is assumed to compose one single cluster in the beginning, and is then divided into
two sub-clusters in an optimal way, and the process is repeated until the bottom of
the hierarchy is reached, i.e., all data points are in their own, terminal clusters. As
there are normally significantly more ways to divide the data points than to combi-
ne them, the agglomerative algorithm is faster and therefore more popular. [39; 45]
Its algorithm can be described in these four steps: [42]
1. Represent each observation as a cluster.
2. Calculate (or update) the distances between all possible pairs of clusters.
3. Combine the two nearest clusters.
4. Return to step 2 if there is more than one cluster left.
Each loop of the algorithm produces one level of the cluster hierarchy. The resulting
dendrogram can be used in finding the best level to cut the dendrogram if a flat
partition is wished. Often, however, the dendrogram itself is the most informative
result of the clustering, at least if one is able to interpret it in order to learn about
the way the data is structured. [42; 39]
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Kuva 2.9: Three common linkage methods used in hierarchical clustering. In single linkage
(visualized on the left) the distance between two clusters is equal to the smallest pair-wise
distance between the two clusters. In complete linkage (in the middle) it is equal to the
largest pair-wise distance. Average linkage (on the right) uses the average pair-wise distance
between the clusters. It is noteworthy that this is not equal to a the distance between the
cluster sample means if dimensionality is over one.
Using hierarchical clustering requires choosing appropriate distance measures for
the data points and for clusters, too. Distance measures between clusters are called
linkage methods, and they all use the distance measure selected for data points. For
this reason, calculating cluster distances requires a pair-wise distance matrix of all
the data points. Four common linkage methods are: [45; 50]
1. Single linkage. In this method, the distance between two clusters is the smallest
possible distance between an observation in one cluster to an observation in
the other one. Vulnerable to outliers, single linkage does not work very well
for large, overlapping clusters but applies to dense, irregularly shaped ones.
2. Complete linkage. In this method, the distance is the largest possible distance
between observations of different clusters. Complete linkage is also vulnerable
to outliers, but applies well for overlapping clusters.
3. Average linkage. In this method, the distance between two clusters is the ave-
rage distance between all possible pairs-wise distances between the clusters.
Average linkage is more robust than the two previous. Additional robustness
is achieved be substituting average linkage to median linkage.
4. Ward linkage. This method defines the between-cluster distance as their within-
cluster variance after merging them. This method tends to produce balanced
clusters.
The first three methods are visualized in figure 2.9. Selecting a linkage method
might require some knowledge about the cluster structure, which, of course, is what
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Kuva 2.10: The two phases in classification. The classifier is trained using labeled training
data. Then it can be used to label new, unlabeled samples.
cluster analysis is assumed to reveal. To overcome this chicken-or-egg-problem, it
might be appropriate to try different linkage methods, study the results, and make
an educated linkage selection for a final analysis based on them. [40]
2.8.4 Classification
Central to supervised machine learning are classification algorithms. Using a set
of labeled observations, they are trained to learn the labels based on the attribute
values of the observations. After the classifier is trained, it can be used to classify
new, unlabeled observations. Figure 2.10 visualizes the training and classification
phases. The observations can be anything ranging from images to expression profiles.
In this section, we introduce some of the main types of classification algorithms.
Instance-based classification
Instance-based classification algorithms use all or part of the observations in the
training set to classify unlabeled observations. One of the most simple classification
method is called nearest neighbor (NN) classification. In NN, the training phase is
minimal: it consists simply of storing the training observations for use in the classi-
fication. It may be preceded by feature selection or extraction and under-sampling
the observation set if necessary. Each unlabeled observation is then classified to
the category of the training observation nearest to it, using any appropriate dis-
tance measure. An incrementally more advanced algorithm is KNN, or k-nearest
neighbors, in which the class is based on a majority vote of the k nearest training
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observations. [38]
Support vector machines (SVM) are a more complicated instance-based approach
to classification. In SVM classification, a subset of the training observations, so called
support vectors, are used to construct a decision boundary between the classes. In
the classification phase, only the support vectors are required to categorize the
unlabeled samples. The decision boundary is constructed in a way which requires
linear separability of the classes, but to overcome this shortcoming, the observations
can be (implicitly) mapped to a higher dimensionality in which linear separability
is achieved. This adds to the computational complexity of SVMs, though it can
by mitigated by using a so called kernel trick. Compared to KNN, however, the
added complexity buys a advantage in memory-usage as only a minority of training
observations have to be stored for classification. [38; 39]
Model-based classification
Similar to model-based clustering, a model-based classifier is trained by fitting pro-
bability density functions to the data. However, as the class labels are known, the
fitting is simpler — EM is not required. Once each class has an appropriately selec-
ted and fitted PDF, unlabeled observations can be classified to the most likely class.
A popular family of model-based classification methods is naïve Bayes classifiers. In
naïve Bayes, each feature is considered independent, meaning that their contribution
in defining the class of an observation can be determined separately. This naïve as-
sumption is strong and potentially restricting, but it allows for a fast training using
a closed-form solution, if maximum-likelihood (ML) estimation is used in fitting the
PDFs. Unlike the name seems to suggest, a naïve Bayes classifier does not require a
Bayesian approach to model estimation. Thus, it is not considered a proper Bayesian
method. The final class probabilities, however, are calculated using Bayes’ theorem,
taking into account the prior class probabilities and class conditional likelihoods [39]:
p(Ck|x) = p(Ck)p(x|Ck)
p(x)
. (2.17)
The classification result is obtained by a maximum a posteriori (MAP) estimate,
i.e. selecting the class with the highest posterior probability.
Despite its inability to recognize dependencies between features, naïve Bayes clas-
sifiers have remained popular for decades. Besides fast training, their simplicity has
another advantage: considering each feature separately restricts the model complexi-
ty, which, in turn, helps avoiding the issues of over-fitting and the curse of dimen-
sionality. [39; 38]
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Kuva 2.11: A simple classification tree. Composed of nodes representing binary decisions,
the model classifies fruits to four categories based on three attributes. Such decision trees
with a small number of nodes are easy to interpret even with very limited understanding
of the theory of statistical classification.
Decision tree classification
Predictive decision trees are perhaps the most intuitive class of classification met-
hods. A decision tree can be visualized by a graph in which each branch point, or
node, represents a decision based on a feature value. Classification of observations is
performed by walking through the tree from the root node to a leaf, or terminal, no-
de. At each node, the observation is passed on to one of the branches sprouting from
the node based on the feature value. Figure 2.11 exemplifies a simple decision tree.
Using features shape, size and color, it classifies fruits to four categories. The red
nodes are decision nodes while green nodes are terminal nodes, each corresponding
to one class.
Classification trees are trained by adding one node at a time, beginning from
the root node. The feature and its threshold value for each node is determined
by maximizing an optimization criterion. One commonly used criterion is Gini’s
impurity, which measures how well the node divides the observation sets. If the
node divides the observations perfectly into separate classes, the impurities of the
resulting groups are zero. If a group contains observations of more than one classes,
its impurity is greater. Gini’s impurity for a subset of observations is defined as [39]
G = 1−
k∑
i=1
p2(i) (2.18)
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where p(i) denotes the fraction of observation in the subset belonging to the i:th
class out of k classes in total. After the optimal feature and its threshold has been
determined for the first node, the same is performed recursively for the following
nodes. A node is considered a terminal leaf when its impurity is zero, the number of
observations in the training set is smaller than a predefined threshold or the number
of successive nodes reaches a predefined maximum. The tree is fully trained when
All terminal leafs fulfill one of these criterions. [39; 38]
Unless the number of nodes in the trained classification tree is very high, the clas-
sifier is relatively easy to understand, visualize and communicate when compared to
most other types of classifiers. If it is simple enough, it can be even used without any
computation by simply walking through the tree manually and comparing the fea-
ture values to the node thresholds. This could be useful, for example, for a clinician
in performing a diagnosis based on measurements and even possible categorical in-
formation (such as risk factors) of the patient. However, classification trees suffer
from one disadvantage: they are notoriously prone to over-fitting. [38] To mitigate
this downside, a resampling-based multi-tree approach has been developed, known
as random forest (RF). [40]
Random forest classification
RF is an example of ensemble classification. An ensemble classifier consists of mul-
tiple sub-classifiers, each trained with a subset (bag) of the entire training data
set. Ensemble classification is used to avoid over-fitting by reducing the variance of
the results. The result of the ensemble classifier is a combined result (often a ma-
jority vote) of the sub-classifiers. In RF, the sub-classifiers are classification trees.
Each tree is trained by sampling, with replacement, a subset of predefined size from
the entire training set. Furthermore, at each node in the training phase, a random
feature selection takes place; only a subset of the features is used. This decreases
the correlation between the trees, which, in turn, increases the generalizability and
outlier tolerance of the forest. [51]
As RF can handle data of almost any type, does not require data normalization,
and is considered rather generalizable, it has gained exceptional popularity within
computational biology and bioinformatics, among other data-intensive disciplines,
since being introduced by Leo Breiman in 2001 [52]. Besides training of RFs, Breiman
introduced a method to rank the features by their predictive value. To do this, the RF
is first trained and the out-of-bag (OOB) error, or classification error of the training
observations not included in the bag of the tree is determined. Then, for each feature,
its values are randomly permutated across the training set. The RF is re-trained with
this modification and its OOB errors are calculated. The importance of the feature
is then determined as the average increase in the OOB error, normalized by the
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Kuva 2.12: Random forest classification. The classifier is an ensemble of decision trees, in
which a random sample of features is used in defining each split within each tree. The final
classification is a majority vote of the individual trees. Randomly restricting the number of
features available for each split decreases the correlation between the trees and, as a result,
enhances the generalizability of the ensemble. Compared to decision tree classification, the
cost for avoiding over-fitting is reduced interpretability.
standard deviation of the tree-specific increases in OOB error. [51]
2.8.5 Classifier validation
Once a classifier is trained, its performance can be evaluated based on its ability to
classify observations not used in the training. This data used to evaluate performance
is called a validation set. Whenever a classifier is trained, it is advisable to use
separate training and validation sets in order to ensure the classifier generalizes,
i.e. performs well with unseen data. If the classifier is able to classify the training
observations well but performs poorly on new data, it suffers from bad generalization
and is over-fit to the training data. Over-fitting means that the classifier has learned
"too much": in addition to the signal, it has modeled noise.
Confusion matrix-based performance measures
The most simple metric for classification performance is classification accuracy, de-
fined as the fraction of correctly classified observations in a set. Alternatively, one
might wish to use the classification error, defined as the complement of accuracy.
Another commonly used and more informative presentation is a confusion matrix
— a contingency table indicating the distributions of the observations over true and
predicted classes. The left panel of figure 2.13 shows a confusion matrix visualizing
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Kuva 2.13: An example confusion matrix presenting the results of three-class classification
(left) and a confusion matrix template for binary classification (right).
the results of a three-category classification. The values of the diagonal elements
tell that most of the observations are correctly classified. Each non-zero value on
non-diagonal elements tells of confusion between classes. In this case, classes 1 and
2 are somewhat confused as observations of both classes are erroneously classified
to the other class. Class 3, however, is well distinguished by the classifier: all of
its observations are correctly classified and only one observation from another class
is misclassified to class 3. Classification accuracy can be easily calculated from the
confusion matrix by dividing the sum of its diagonal by the sum of all elements.
The right panel of figure 2.13 shows the confusion matrix template for binary
classification, i.e., a two-class classification. In binary classification, the two classes
are often seen as positive and negative, such as face recognized versus not recognized,
or in reference to diagnosis of a disease. In the binary confusion matrix, there are only
two elements corresponding to misclassifications: false positives and false negatives.
A low number of false positives means that the classification has high specificity while
low number of false negatives means high sensitivity. Both properties, of course, are
desirable, but some times it may be useful to prefer one over the other. For example,
in diagnosing a serious disease requiring immediate treatment, false positives are not
as harmful as false negatives. Specificity is defined as
Specificity =
nTP
nTP + nFP
(2.19)
and sensitivity as
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Kuva 2.14: Receiver operator characteristic curves of two classifiers. Classifier A has a
higher sensitivity and specificity as classifier B for all values of a parameter used here to
study the tradeoff between sensitivity and specificity.
Sensitivity =
nTP
nTP + nFN
, (2.20)
where nTP is the number of true positives, nFP false positives and nFN false nega-
tives. [40]
A useful tool in adjusting the tradeoff between sensitivity and specificity is a
receiver operator characteristic (ROC) curve. Figure 2.14 shows ROC curves of two
classifiers. A ROC curve is obtained by varying the value of a classifier parameter
and calculating the sensitivity and specificity for every value. The sensitivity is then
plotted against 1 – specificity. Looking at the curve, a suitable tradeoff between sen-
sitivity and specificity can be obtained by selecting an appropriate parameter value.
The dashed line from (0, 0) to (1, 1) represents the most likely performance of a
random, untrained binary classifier. The red curve represents a classifier somewhat
better than a random binary class assigner, and the blue curve represents an even
better classifier. ROC curves can also be used to determine a robust performance
metric known as area under curve (AUC) by integrating the ROC curve (i.e., calcu-
lating the area under it) from 0 to 1. The resulting metric is independent of the
parameter value. [40]
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Resampling-based performance estimation
When dividing the data into training and validation sets, both should be sufficiently
representative of the signal, i.e., patterns present in the data. Normally, classifier
performance is weighted more important than having an accurate estimate of the
performance and. As a result, the split between training and validation sets is asym-
metrical, favoring the training set. If, however, the entire observation set is very
small (for instance, if the number of observations is smaller than that of features),
resampling-based approaches can be used to overcome the problem. [38]
The perhaps most popular resampling-based method of classifier performance
estimation is cross-validation (CV). In cross-validation, the classifier is trained mul-
tiple times with subsets of the data, with the left-out observations used to validate
the classifier. In k-fold CV, the data is split k times such that the validation set
comprises one kth of the data and is entirely separate in each fold. n 10-fold CV,
for instance, a 90 % of the observations is used to train the classifier ten times, with
separate 10 % validation sets. The final classifier can then be trained with the entire
set and its accuracy estimated as the average accuracy of the folds (and similarly
for other performance measures). It is important to remember, however, that the
estimated accuracy is not precisely that of the final classifier, but rather a somewhat
artificial estimate. For this reason, cross-validation should be used in performance
estimation only if splitting the data into separate training and validation sets really
risks compromising the signal-to-noise ratio of the sets. [38]
A method similar to CV used in classifier training, not performance estimation,
is bagging. It means involves training multiple classifiers with different samples of
the training data, and constructing the final classifier as an ensemble of the sub-
classifiers. The goal is to reduce over-fitting, and, thus, enhance the classifiers gene-
ralizability. [39] Random forest, discussed in the previous section, is an example of
a resampling-based ensemble classifier.
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3. MATERIAL AND METHODS
3.1 Data
The data used in this thesis is publicly available gene expression microarray data
from the GEO repository. Over the years, researchers around the world have con-
ducted microarray experiments and uploaded the resulting data to public, resulting
in a impressive collection of hundreds of thousands of entries from the entire spect-
rum of bio-medical fields. The true value in such a database is that it allows for
an abundance of data-driven analyses across multiple conditions — both healthy
and disease — with sample sizes great enough to produce results of extremely high
statistical significance. Merging and analyzing large sets requires at least
1. careful selection of the data sets to include in analysis,
2. manual curation of the entries to ensure congruent annotations, or meta data,
3. computational methods to normalize the data to mitigate the variety of tech-
nical differences, or batch effects, between data sets and
4. computational methods and resources capable of handling the down-stream
analyses of high-dimensional data.
This thesis centers on approaches dealing with the latter two issues. The aim was
to analyze a comprehensive hematological gene expression set. Toward this end, a
collection of data sets (known in GEO as series and identified by a unique ID called
GSE numbers) collectively comprising raw intensity data of over 10,000 individual
microarrays (identified in GEO by IDs called GSM numbers). GEO hosts data from
various microarray platforms, but only entries produced by the Affymetrix GeneChip
v 2.0 plus was chosen since it is the most common platform among GEO entries and
cross-platform analyses face major technical disadvantages. [53; 4]
After preliminary quality control, 9544 samples remained. The composition of
the set is visualized in the charts of figure 3.1. The majority of samples (7,279)
are biopsies from hematological tumors or proliferative disorders. The rest consists
of healthy cells of hematological origin (1,006), blood cancer cell lines (862) and
miscellaneous samples (397), such as normal cell samples from cancer patients.
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Kuva 3.1: Composition of the hematological gene expression data set.
Metadata of the samples were collected and merged in a single table in a stan-
dardized fashion (outside of the scope of this thesis). This included further disease
or cell type categories, genetic features, clinical parameters, basic information of the
patient (such as sex or age) and information on the study for which the data was
originally produced. Metadata was not available in the same detail for all samples.
For example, for some patients the age is unknown, and cytogenetical information is
known for only a minority of the tumors. Thus, any approach utilizing the metadata
will have to handle its sparsity or the samples with insufficient annotations have to
be left out of that particular analysis.
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Kuva 3.2: Data dispersion as a function of its location in the three pre-processing steps.
In the scatter plots, each point represents a single array of the data set. Dispersion is
measured by the interquartile range (IQR) of the log2-intensities of an array and location
as its median log2-intensity. Panel A shows the raw data. Arrays with deviating IQR-
median positions were discarded as outliers. B shows RMA-normalized data which, due to
normalization, occupies a smaller area in the IQR-median space. In C, the bias corrected
data occupies an even smaller area. Notice the different scales of the plots.
3.2 Pre-processing
The raw intensity data for each microarray were downloaded from GEO as CEL-
files. They contain intensities in numerical form of each probe on the array. To
ensure the data quality, the IQR of the intensities of each array was plotted against
their median, both on a log2-scale. Cut-off values for discarding outlier arrays were
determined by visually inspecting the IQR-median scatter plot of all 11,597 arrays.
As figure 3.2 illustrates, only arrays with log2-IQR within (5.5, 8.5) and log2-median
within (0.75, 2.25) were selected for further pre-processing. Also, as some arrays have
been submitted to GEO under different GSM IDs, the duplicates were removed at
this stage.
RMA was chosen for normalization and summarization of the probe intensities
to probe set (gene) expression level, since RMA has an implementation for extraor-
dinarily large data sets. It is implemented as an R-function justRMALite in the
affyExtensions R-package, and is designed by RMA developers to normalize extre-
mely large data sets [54]. To further mitigate batch effects, a bias correction tool,
likewise implemented as an R-function, was used in gene-wise elimination of the li-
near relationship between four bias metrics and gene expression [55]. The metrics
include 1) the IQR of the array raw intensities, 2) the median of the raw intensities,
3) the IQR of the RMA-normalized array expression values and 4) RNA degrada-
tion values estimated for each probe set based on its probes. This bias correction
step was performed after RMA-normalization.
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After pre-processing, the 62 control probe sets included in the array were discar-
ded. Their expression varied greatly across the arrays, suggesting that RNA-spike-in
was performed in only a part of the arrays [32]. Therefore, they were deemed use-
less in the context of this data set. All of the pre-processing was performed in R
using applicable R-packages. All subsequent analysis was performed in MATLAB
environment.
3.3 Dimensionality reduction
PCA was used to visualize the data set and examine the source of its variance.
Although not necessarily the best method of carrying the most essential informa-
tion of the data set into lower dimensions, the simplicity of the method and the
interpretability of PCs favored the choice. PCA was performed at three levels, or
disease-specific sample subsets, of the data set to demonstrate the different levels of
information carried by the data and to verify if the multiple-source data is compa-
rable at different levels of detail. The three selected levels were 1) all cancer samples,
2) all leukemia samples and 3) all pre-B-ALL samples. Since pre-B-ALL samples had
detailed cytogenetical annotations available, they were selected as the most detailed
level in the analysis.
For the further analyses, the dimensionality was reduced by leaving out all genes
with low variance across the data set, as this has been shown to enhance the per-
formance of down-stream analyses [56]. The threshold was determined separately in
each analysis by plotting the sorted variances and selecting an appropriate value to
obtain only the genes with significant variance and, presumably, containing or sig-
nal instead of mere noise. The number of genes with high variance depends on the
number of phenotypes represented by the data. Therefore analyses with a restricted
set of disease subtypes use a lower number of genes.
3.4 Cluster analysis
Cluster analysis was performed to study how well disease groups can be distin-
guished from the data in an unsupervised manner. To test the separability in a
phenotypically restricted subset, pre-B-ALL was selected for the analysis. Perfor-
ming cluster analysis in a group with low biological variance facilitates identifying
technical artifacts such as the array effect.
Agglomerative hierarchical clustering was selected to avoid the problem of pre-
selecting the number of clusters, distribution types (in model-based clustering) and
other parameters (in, for example, DBSCAN). Moreover, the additional informa-
tion on possible patterns present in the data provided by the resulting dendrogram
supported the decision. Ward linkage was used since it tends to produce robust, ba-
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lanced clusters [57; 58]. Euclidean distance was selected as the distance measure. To
reduce the amount of noise, only genes with significant variance across pre-B-ALL
samples were selected.
3.5 Subtype prediction
Supervised classification of the cytogenetical subtypes of pre-B-ALL samples was
performed to further assess the separability of the subgroups and to characterize
their transcriptomic differences. RF classification was selected for this task as it has
proven suitable, and popular, for gene expression studies, especially because of its
ability to avoid over-fitting. Also, it has been proposed as a method to identify gene
sets relevant in characterizing the differences between multiple phenotypes. [60; 59]
Before classifier training, the data set of 664 pre-B-ALL samples with cytogene-
tical annotations available were divided to a training set of 399 and validation set
of 265 samples (a 60/40 split). The number of samples per class was assumed to be
sufficient in both the training and validation set. Variance filtering of genes was used
before the classification, resulting in a dimensionality of 510. The fraction of trai-
ning samples to be used in training of a single tree was set to 80% and the fraction
of genes to be used per tree was set to 20 (rounded square root of dimensionality).
The number of trees was defined by observing the out-of-bag error rate for forest
sizes ranging from 1 to 100 trees. The OOB error appeared to decrease until approxi-
mately 20 to 25 trees, and therefore, the forest was set to 25. The final validation of
the model was performed by classifying the unlabeled validation set. The increase
in OOB error when the expression values of a gene were randomly permutated was
used to assess the its predictive value.
3.6 Lineage identification
To uncover the nearest healthy gene expression state of a tumor, euclidean distances
(as defined by equation 2.7) between each cancer-normal sample pair were calcula-
ted. Before calculating the distances, the genes were variance-filtered, resulting in a
feature dimensionality of 1,720 genes.
Figure 3.3 visualizes the process of defining the nearest normal state. Once the
distances were determined, the nearest normal sample for each cancer sample was
then used to define its nearest normal expression state. This was done by selecting
the two nearest samples of the previously found nearest normal sample, within its
cell type. The resulting nearest normal state is defined by the three normal samples,
all of which represent the same cell type.
The method falls into the mid-ground between two more naïve approaches. The
first would be to select the nearest normal neighbor and treat it as the nearest
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Kuva 3.3: Finding the nearest healthy gene expression state for a tumor. Panel A visualizes
a cancer sample in the same gene expression space as samples from three different normal
cell types. First, the nearest normal sample is identified (B). Then, the two nearest samples
to the one found in the first step are identified, with the criterion that they must all
represent the same cell type (C). Finally, the resulting three normal samples are used to
model the nearest stable healthy state of the cancer sample (D).
normal state. This approach, although simpler, is not very robust: defining a stable
expression state based on a single microarray measurement is vulnerable to biases
and does not appreciate the intrinsic biological variability within the state. The
other approach would be essentially NN classification: defining the nearest normal
state as the entire sample population of the cell type represented by the nearest
normal individual sample. This method would overcome both of the issues of the
first approach. However, it does not appreciate the fact that samples of the same cell
type might comprise multiple sub-populations, each representing a separate stable
state within the cell type. Also, the expression states of different cell types may
inhabit spaces of different sizes and shapes. As we are interested in finding the
closest stable state, a part of a larger normal state, or attractor, is sufficient, and
even desirable. Moreover, defining the normal states as a fixed amount of samples
facilitates comparing the divergences of different cancer samples.
The number of normal samples defining a stable normal state was set at three
because the smallest number of samples within a normal cell the in the data set
is three. If it was higher, a larger amount could have been chosen, but it is not
clear which number would be an optimal tradeoff between robustness and biological
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meaningfulness. The selected method does suffer from some vulnerability to outliers,
though, as a single biased sample may have effect on the defined normal state.
After the nearest normal state of each cancer sample had been identified, their
regulatory divergence from the normal state was quantified by estimating the number
of differentially expressed TFs between the malignant and normal state. A set of
2,118 TF and other regulatory genes were selected from the entire set f 17,612
genes. Low-variance TF genes were further excluded by thresholding in a similar
way as in the previous step. As a result, 440 TF genes were deemed informative of
the gene-regulatory state.
Three criteria were placed for differential expression. First, an absolute expression
difference of 100 was required in order to exclude noise present in very low expression
values. Secondly, an expression fold-change of 1.5 was required to ensure biological
relevance of the difference. Lastly, a two-tailed t-test was performed to ensure that
the difference between the malignant and normal state expression values is likely not
to be zero-centered. The resulting p-values were corrected for multiple testing using
a method proposed by Storey [61]. The significance threshold for corrected p-values
was set at 0.05.
Any TF satisfying the three above-mentioned criteria was considered differentially
expressed between the malignant and normal state. The regulatory divergence of the
cancer sample in question was defined as the number of differentially expressed TFs.
As each malignant state is modeled by a single sample in this method, they are likely
to suffer from technical biases. However, the number of samples within any cancer
subtype is presumably high enough to reveal the true pattern and mitigate the noise.
Naturally, the signal-to-noise ratio is best with the largest cancer subtypes.
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4. RESULTS AND DISCUSSION
4.1 Gene expression landscapes of cancer
Principal component visualizations attempt to preserve as much information of the
difference between samples as possible. The PC coordinate system is orthogonal,
meaning that the information carried by a PC is independent to all other PCs,
and likely conveys its own biological interpretation. The PCs can be interpreted
one at a time based on how the different disease groups are projected to it. If a
PC separates to different phenotypes, it carries information on their difference. In
this section, we interpret PCA results by characterizing the PCs on their ability
to separate groups. The biological interpretation can be further characterized and
validated based on the genes which contribute most to the PC, i.e. have the highest
(positive or negative) loadings. Some PCs give no apparent information on when
viewed in the context of few disease groups. In such cases, the information is more
detailed and requires taking a look at the genes behind the PC. They can reveal a
true biological phenomenon independent of disease groups, or, possibly, be artifacts
due to batch effects.
Visualizing all the cancer samples in the dataset using PCA yields a unique birds-
eye view on the transcriptomic landscape of hematological malignancies. Figure 4.1
shows all of the cancer samples along the first two PCs (left panel) and first and third
PCs (right panel). Coloring the samples according to their type of hematological
malignancy and lineage reveals how the samples of similar cancer tend to group
together. Most notably CLL samples are grouped together, separate from all other
groups. ALL and AML lay close, partially overlapping, while AML and CML, both
malignancies of the myeloid lineage, occupy nearly the same space in this two-
dimensional PCA plane. Lymphomas and multiple myeloma, both malignancies of
more differentiated lymphocytes, also occupy nearly the same space. The first two
PCs, however, clearly separate the malignancies of blast cells (leukemias) and those
of differentiated hematopoietic cells (lymphocytes and multiple myeloma) from each
other. Furthermore, they organize leukemias into a lineage-based order, with acute
leukemias in the center and their corresponding chronic counterparts to their sides.
The right panel of figure 4.1 reveals the information carried by the third PC:
it separates lymphomas from myelomas, which appeared transcriptomically similar
in the context of the first two PCs. Similarly, each following PC carries its own,
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Kuva 4.1: PCA of all cancer samples. Coloring the samples based on the eight main cate-
gories of malignancies within the data set reveals that the three first PCs clearly separate
four groups: 1) multiple myeloma, 2) lymphoma, 3) CLL and 4) AML, ALL and CML.
independent level of information of the transcriptomic variance within all cancers
of hematopoietic origin. The fourth and fifth principal components of this pan-
cancer analysis are found in the appendix (A.1) The amount of information, however,
becomes more and more subtle with each following PC. The first two PCs explain
23.6 % of all variance, which is a disproportionally high fraction considering the
total amount of PCs (17,612). The number of PCs needed to explain 99 % of the
variance is 521, meaning that the intrinsic dimensionality is significantly lower than
the actual number of features (genes). However, the finding is not surprising in
the context of high-throughput measurements, where highly correlating features are
commonly found within the data. Table 4.1 summarizes the interpretation, main
contributing genes and variance of the first five PCs.
Taulukko 4.1: Characterization of the top principal components of all hematological
cancers.
PC Interpretation Top gene (+) Top gene (−) Variance
1 LYM & MM vs. LEU GPNMB AZU1 12.6 %
2 Myel. vs. lymph. LEU RRM2 KIAA0226L 11.0 %
3 LYM vs. MM CXCL13 SDC1 7.9 %
4 Lymph. vs. myel. LEU DNTT FCN1 5.2 %
5 Myeloid vs. lymphoid ATP8B4 TUBB2A 3.6 %
Performing PCA for a subset of cancer types reveals more detailed information
on the specific set while compromising information of the wider context. Figure 4.2
visualizes the PCA of leukemia samples. It clearly gives more leukemia-specific infor-
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Kuva 4.2: PCA of all leukemia samples. The greatest independent source of variance within
the data is explained by the transcriptomic differences between CLL and all other leuke-
mias. The second PC explains differences between ALL and myeloid leukemias, nut the
third PC carries no apparent information regarding the subtypes of leukemia.
mation. The first PC separates CLL from other leukemias while placing ALL, speci-
fically pre-B-ALL closer to CLL than other leukemias. This reflects the fact that
ALL and CLL are both cancers of the lymphoid lineage. ALLs of B- and T-lineage
are somewhat overlapping. The second PC separates ALL from myeloid leukemias.
Interestingly, it also separates CML into two distinct groups, both overlapping with
AML. The third PC, however, is more difficult to explain by this five-class leuke-
mia grouping. It disperses all of the groups approximately equally. Further study is
required to determine if this variance is explained by a true biological phenomenon
instead of a technical artifact The fourth PC separates T- and B-ALL while the
fifth divides CML into two subgroups similarly to the second PC (A.2). Table 4.2
summarizes the leukemia-specific PCs.
Taulukko 4.2: Characterization of the top principal components of leukemias.
PC Interpretation Top gene (+) Top gene (−) Variance
1 Other LEU vs. CLL AZU1 POU2AF1 19.7 %
2 ALL vs. myeloid LEU DNTT CSTA 8.8 %
3 ? TUBB2A GAPT 6.2 %
4 pre-B-ALL vs. T-ALL CTGF ITM2A 4.6 %
5 Divides CML S100A12 CPA3 3.9 %
Moving to an even more deeper level of information, figure 4.3 and table 4.3 show
the results of PCA for pre-B-ALL. Only the samples belonging to one of the common
cytogenetic subgroup were selected in order to study the transcriptomic differences
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Kuva 4.3: PCA of pre-B-ALL samples. Within pre-B-ALL, PCA reveals differences between
the cytogenetical subtypes, though the separation is not as clear as in main types of
leukemia. Noise and artifacts are likely to cause more variance in sample sets of specific
disease subtypes as the biological variance decreases.
between these groups. Three of the groups represent recurrent chromosomal trans-
locations (t(12;21), t(1;19) and t(9;22)), one represents MLL-rearrangements and
one hyperdiploid karyotype. Interestingly, the first two PCs carry essentially the sa-
me information: they separate MLL and t(12;21) groups, leaving the remaining three
in between. The first two PCs have also high variance in a direction perpendicular to
this separation. In this direction, however, no separation between the classes is seen.
The third PC separates t(9;22) from t(1;19) with HD group overlapping t(9;22),
suggesting gene-expression similarity with the two groups. The fourth and fifth PCs
further separate the groups (A.3).
Taulukko 4.3: Characterization of the top principal components of pre-B-ALL.
PC Interpretation Top gene (+) Top gene (−) Variance
1 t(12;21), vs. MLL MME MEIS1 10.0 %
2 MLL vs. t(12;21) LAMP5 SHANK3 9.7 %
3 t(9;22) vs. t(1;19) S100A12 PRKCZ 7.0 %
4 HD vs. t(9;22) IRX1 IGJ 4.8 %
5 t(12;21) vs. HD S100A12 S100A16 4.1 %
The first three PCs suggest that the cytogenetical subtypes have distinct ge-
ne expression patterns. Even though they do not separate linearly in the two-
dimensional plots, the full-dimensional representation of the data is likely to dis-
tinguish the classes more clearly. Figure 4.4 shows a two-dimensional projection of
the three first PCs of pre-B-ALL samples. This projection was manually selected to
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Kuva 4.4: Three-dimensional PCA of pre-B-ALL samples. Appropriately selecting a two-
dimensional projection of the first three PCs reveals that the pre-B-ALL subtypes represent
distinct gene expression profiles, though some overlap between subtypes is present in this
PC space.
separate the classes, and it indeed separates them better than either two-dimensional
plot of figure 4.3.
4.2 Cluster analysis
PCA hinted that the the cytogenetical subtypes of pre-B-ALL are separable in the
gene expression space. To further assess this, hierarchical clustering was performed
for all pre-B-ALL samples belonging to one of the five most common cytogenetical
subtypes. Although pre-B-ALL is generally considered a single disease, the cytoge-
netics have been shown to be indicative of survival and, thus are likely to represent
slightly different phenotypes.
Figure 4.5 shows a heat map of the expression profiles of pre-B-ALL subtypes with
both genes (rows) and samples (columns) clustered. Cutting the dendrogram at the
level of five clusters yields clusters with high concordance with the five cytogenetical
subtypes. Cross-tabulation of the cytogenetical annotations and cluster assignments
of the pre-B-ALL samples are shown in table 4.4. Over 90 % of samples in each
cluster belong to a single subtype. Cluster 2, consisting of only t(1;19)-samples,
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Kuva 4.5: Hierarchical clustering of pre-B-ALL. Selecting the cluster partition at the level
of six clusters reveals that the six cytogenetical subtypes are the most defining source of
variance at this scale of the data. Apart from a few outliers, all clusters correspond to
a distinct subtype. The expression profiles reveal subtype-specific patterns, but one gene
cluster (marked in red) appears to have high variance within each cluster. Thus, it is likely
to explain a biological phenomenon unrelated to the cytogenetics. This cluster is visualized
in the appendix with its gene namesA.4.
is the purest, meaning that the fraction of its most representative class is 100 %.
The most impure is cluster 3, with 90.8 % of t(9;22)-samples. Considering the gene
expression-wise separability of the classes shown in 4.4, this appears to reflect the
fact that t(9;22) group overlaps with other groups, at least in PCA. Subtype purities,
i.e. fraction of samples in a subtype in the same cluster, range between 93.4 % and
99.4 %. The overall purity, i.e. fraction of samples in the most representative cluster,
is 96.4 %.
Taulukko 4.4: Cross-tabulation of the subtypes and cluster assignments of pre-B-ALL
samples.
Clust. 1 Clust. 2 Clust. 3 Clust. 4 Clust. 5 Purity
MLL 177 0 0 1 0 99.4 %
t(1;19) 2 71 3 0 0 93.4 %
t(9;22) 1 0 139 2 3 95.9 %
HD 0 0 7 121 0 94.5 %
t(12;21) 0 0 4 1 132 96.4 %
Purity 98.3 % 100.0 % 90.8 % 96.8 % 97.8 % 96.4 %
The fact that the five clusters produced by hierarchical clustering so clearly corres-
pond to the five cytogenetical subtypes reveals that the subtypes represent separate
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states in the gene expression space. Furthermore, at this level of detail, cytogenetics
explains the gene expression differences better than any other parameter such as
age, gender, cancer stage or the possible batch effect. The heat map reveals, howe-
ver, a cluster of genes with significant variance in expression within pre-B-ALL, yet
no correlation to the subtype. In figure 4.5, this gene cluster is marked in red in
the dendrogram to the left of the heat map. In each subtype, there are samples in
which the expression of the genes in this cluster are high and others in which it is
low. A heat map with these genes (and their names) across pre-B-ALL samples is
shown in A.4. Interestingly, the genes appear to be neutrophil specific. This suggests
that some of the pre-B-ALL samples have been impure, containing neutrophils, or
that some of the pre-B-ALL tumors have activated neutrophil pathways. Finding
the biological reason for the phenomenon would require some further research.
4.3 Subtype prediction
Unsupervised methods of dimensionality reduction and clustering revealed that the
cytogenetical subtypes of pre-B-ALL have distinct gene expression profiles. To furt-
her study their separability and to determine the genes most responsible for the dif-
ferences between the subtypes, supervised random forest classification was applied
to pre-B-ALL samples. The classification confusion matrix for the test data set of
267 samples is shown in table 4.5. The total classification accuracy is 95.9 %, mea-
ning that the RF classifier performs on new data essentially as well as unsupervised
clustering in separating the five cytogenetical subtypes. Subtype-specific sensitivi-
ty ranges from 90.6 % in t(1;19) to to 100 % in MLL. The specificity of classes is
somewhat higher, ranging between 93.8 % and 100 %. The subtype-specific sensiti-
vities and specificities correspond to the cluster- and subtype specific purities of the
cluster analysis.
Taulukko 4.5: Confusion matrix of pre-B-ALL random forest classification.
Predicted class
MLL HD t(12;21) t(1;19) t(9;22) Sensitivity
Tr
ue
cl
as
s MLL 70 0 0 0 0 100.0 %
HD 1 39 0 0 3 90.7 %
t(12;21) 0 1 55 0 0 98.2 %
t(1;19) 2 0 0 29 1 90.6 %
t(9;22) 1 1 1 0 61 95.3 %
Specificity 94.6 % 95.1 % 98.2 % 100.0 % 93.8 %
Figure 4.6 shows a heat map of the genes with the highest predictive value in
classifying pre-B-ALL samples. It reveals clusters of genes with clearly subtype-
specific expression patterns. For example, one can see genes which are specifically
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Kuva 4.6: A gene expression heat map representing subgroups of pre-B-ALL and their
RF-predicted classes. The expression profiles include only the genes deemed predictively
important in RF classification. Subtype-specific patterns are strikingly clear.
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Kuva 4.7: The training set (left) and validation set (right) of RF classification. All of the
training samples were classified correctly by the trained RF, but eleven validation samples
were misclassified. The incorrectly classified samples are marked with red circles in the right
panel. Some of them appear to be clear outliers and possible misannotations while others
are due to non-separability between classes. The PCA used to create this projection was
performed by using only the predictive genes listed in 4.6 to obtain class separability. Thus,
the PCA cannot be considered fully unsupervised. It does, however, reveal the separabilities
of different classes well.
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up-regulated in one subtype: MEIS1 in MLL, DDIT4L in HD, PTPRK in t(12;21),
PBX1 in t(1;19), and GBP5 in t(9;22). Most genes in 4.6, however, are up-regulated
in several subtypes and down-regulated in others. All of them nevertheless contribute
to the classification accuracy.
The genes with predictive value in RF classification were used to visualize the
subtype separability. Figure 4.7 shows a PCA of the predictive genes. This PCA is
not unsupervised in that the features (genes) were preselected to yield class separabi-
lity. However, it reveals how well the classes separate. Apart from a few outliers, the
MLL, t(12;21) and t(1;19) subtypes form clearly distinct clusters in the PC-space.
HD and t(9;22) samples, however, partially overlap. The left panel of figure 4.7 vi-
sualizes the samples used to train the RF classifier and the right panel shows the test
set. All of the training samples are correctly classified by the classifier, but eleven
test samples, marked by red circles in the PCA plot, out of 265 were misclassified.
Besides obvious outlier samples, possibly mislabeled, the wrongly classified samples
include HD and t(9;22) samples which, apparently, are misclassified because of class
the overlap. This suggests that the areas of the gene expression space for these two
classes, i.e., their gene-regulatory attractors, are closer to each other than to any
other pre-B-ALL subtype, and might even overlap.
4.4 Cancer lineage identification
Figure 4.8 visualizes the results of lineage identification of hematological malig-
nancies and proliferative diseases. The graphs show the closest normal cells of the
patient samples in each disease group. The width of the edges between a cancer and
normal cell node is proportional to the fraction of samples in the cancer subtype
which were gene expression-wise closest to the respective normal cell. All fractions
less than 10 % of all samples in the respective cancer subtype are omitted from the
graph for clearer visualization and to avoid modeling noise. The graphs reveal that
most cancers have two nearby normal states. In very few subtypes of hematological
malignancies do over 90 % of the patient samples have the same closest normal sta-
te. These include pre-B-ALL with MLL rearrangement (closest normal cell HSC)
and CLL (resting B-cell).
Especially in the case of leukemias, the graph suggests that the malignant state
is somewhere between HSC and a mature hematopoietic cell. All AML subtypes, for
example, are linked to both HSC and monocyte, a mature myeloid cell. Most pre-B-
ALL subtypes, in turn, are linked to HSC and a B-lymphocyte while T-ALL is linked
to HSC and a T-lymphocyte. The strong association to HSC in all acute leukemias
reflects the fact that leukemic cells are immature blasts which have retained, and
possibly even regained, stem cell-like properties such as replicative potential.
Unlike leukemias, lymphomas do not show any association to the HSC but, rather,
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mature hematopoietic cells. Interestingly, several lymphomas are strongly linked to
macrophages and monocytes, even though they are cells of the myeloid, not lymphoid
lineage. This seems to suggest that the solid lymphoma samples suffer from purity
issues. In other words, the lymphoma samples seem to contain significant amounts of
myeloid cells. The fact that these cells are specifically macrophages and monocytes
might be due to 1) them being activated in fighting against the tumor cells, 2) them
being recruited by the tumor or, perhaps most likely 3) them being common cells
in the locations where lymphomas tend to form, i.e., lymph nodes.
Also present in figure 4.8 is the top TFs for each cancer-normal link defined as the
TF which is most commonly differentially expressed within the patients and normal
their closest cell type. If multiple TFs were equally frequent in this respect, the one
with highest absolute expression difference was selected. The top TFs, not surpri-
singly, represent many of the central hematopoietic regulatory genes implicated in
tumorigenesis. However, to appreciate the complexity of the regulatory aberrations,
one TF likely to not be sufficient.
Figure 4.9 shows the regulatory divergences of cancer subtypes to their closest
normal state as measured by differentially expressed TFs. In most cases, the di-
vergences within a subtype are widely distributed. Some systematic patterns are,
however, visible. Acute leukemias, in general, are farther from their nearest normal
states than lymphomas. Specifically, cancer samples whose nearest normal state is
the HSC, tend to have greater regulatory divergences. Interestingly, most pre-B-
ALL subtypes are divided into samples associated to the HSC and those associated
to B-lymphocytes. As the samples associated to B-cells are systematically closer to
their nearest normal state, it seems that there is two pre-B-ALL sub-populations:
the ones closer to HSC and those closer to B-cells. This could, however, result from
impure samples containing normal B-cells in addition to leukemic blasts.
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5. CONCLUSIONS
The work presented in this thesis is centered around a hematological gene expression
data set downloaded from a public repository. Although available for anybody with
an internet connection, this type of data is next to useless without an understanding
of the technical and biological biases present in multiple-source data and a means of
addressing them properly. Furthermore, analyzing high-dimensional biological data
spanning a plethora of hierarchically organized phenotypes requires state-of-the-art
approaches of data mining, and even developing novel computational methods.
The main challenge in integrating data produced by hundreds of different labo-
ratories around the world is to ensure that the data is comparable. This issue was
addressed in multiple steps: discarding low-quality measurements before integration,
collective normalization the measurements, correcting for four separate sources of
bias across the entire data set, and performing down-stream analyses to validate
the comparability. PCA revealed that the variance in the data set — whether ana-
lyzing thousands of cancer samples or a restricted set representing a specific disease
subtype — was explained by the phenotype, not the producer of the data. In the
exemplary case of pre-B-ALL, both unsupervised and supervised machine learning
approaches were able to separate the cytogenetical subtypes with high sensitivi-
ty and precision, confirming that the integrated and bias-corrected expression data
indeed enables cross-study analyses in highly specific settings.
Undoubtedly the good comparability of the integrated data stems, at least in
part, from the sheer size of the data set: the high number of both phenotypes and
instances thereof allows for 1) high-confidence detection of failed measurements as
outliers, 2) a robust, low-bias estimation of the intensity distribution in quantile
normalization as well as 3) high-quality estimates of the linear dependency between
the four bias metrics and probe set expressions. Moreover, the number of instances
in the data set enables drawing conclusions with a higher statistical significance
than in single studies with a limited patient cohort. Thus, the results suggest that
assembling similar data sets in the context of other diseases and healthy conditions
likewise could benefit especially in analyses involving multiple phenotypes.
Characterizing leukemias, lymphomas and multiple myeloma as aberrant states
of the gene regulatory system provides a novel systems biological birds-eye view
to the family of cancers arising from the hematopoietic lineages. The characteriza-
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tion is unique in its comprehensiveness of hematological diseases and the size of
the cohort used to generate it. Studying the cancer-normal state associations and
the corresponding quantified regulatory divergences yields a pan-hematological or-
ganization of myeloid and lymphoid malignancies as abnormal, immature cellular
states, gene regulatory-wise somewhere between the hematopoietic stem cell and
fully differentiated cells. Also, it highlights the issue of sample purity, presumably
a more significant problem in solid tumors than liquid ones. Fortunately, several
computational methods have been developed to purify samples in silico utilizing
the known expression profiles of different tissues. They could prove to be crucial in
saving a large proportion of gene expression data available in public repositories,
possibly suffering from poor sample purity.
Revealing and quantifying the regulatory deviations of malignancies provides a
new framework for cancer drug discovery. Finding any means to nudge the gene re-
gulatory system to change its attractor away from the malignant state would cure
cancer. Knowing the goal, or the closest normal attractor, and the regulatory diver-
gence from it, is useful in determining a rational approach to push the regulatory
system of a cancer cell to the right direction. Conventional ways to treat cancer
— surgery, x-ray and chemotherapy — do not cure the disease in many cases. For
this reason, it is fruitful to study the system-level properties of cancer cells in order
to detect specific types of malignancies which might have a healthy state within a
surprisingly short regulatory distance.
This thesis manages to grasp only a small, yet promising, sliver of the potential
in combining and re-using data constantly produced by the worldwide biomedical
research community and stored in massive repositories. Further potential lies in in-
tegrating the microarray-based expression data to that of newer, next-generation
sequencing-based technologies. Even though RNA-sequencing provides valuable ad-
ditional information to the expression profiles, the number of microarray measure-
ments available is likely to outnumber that of RNA-sequencing for years. Therefore,
user-friendly methods to render data from different measurement systems compa-
rable will hold their value.
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Kuva A.1: The fourth and fifth principal components of all cancer samples against the first
principal component.
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Kuva A.2: The fourth and fifth principal components of all leukemia samples against the
first principal component.
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